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1. INTRODUCTION 
 
1.1.Introduction to Herbal medicine 
 The World Health Organization (WHO) has recently defined traditional medicine 
(including herbal drugs) as comprising therapeutic practices that have been in existence, 
often for hundred of years, before the development and spread of modern medicine are still 
in use today .Or say , traditional medicine is the synthesis of therapeutic experience of 
generations of practicing physicians of indigenous systems of medicine. The traditional 
preparations comprise medicinal plants, minerals ,organic matters for medicinal purposes, 
and the investigation of such use. Plants were been the basis for medical therapies through 
much of human history, and such traditional medicineis still widely practiced till date
1
. 
Modern medicine distinguishes herbalism as a form of alternative medicine, as the practice 
of herbalism is not strictly based on evidencegathered using the scientificmethod. 
 Archaeological proof indicates that the use of medicinal plants dates at least to the 
Paleolithic, approximately 60,000 years ago. Written evidence of herbal medicines dates 
back over 5,000 years, to the Sumerians, who created lists of medicinal plants. A number of 
ancient cultures wrote on plants and their medical uses. In ancient Egypt, herbs are cited in 
Egyptian medical papyri, portrayed in tomb illustrations, or on rare 
occasionsfoundinmedicaljarscontainingtraceamountsofherbs. Theearliest recognized 
Greekherbals were those of Diocles of Carystus, written during the 3rd century B.C, and one 
by Krateuas from the 1st century B.C. Only a few fragments of these works have lasted 
intact, but from what remains scholars have noted that there is a large amount of overlap 
with the Egyptian herbals
2
. Herbs were also common in the medicine of ancient India, where 
the prominent therapy for diseases was diet. De MateriaMedica by Pedanius Dioscorides a 
Roman physician, is a particularly important exampleof such writings. The certificationof 
herbs and their uses was a central part of both Western and Eastern medical scholarship 
through to the 1600s, and these works played amajor role in the development of the science 
of botany. 
 
 
 
 
1.2.Prevalence of use 
 
 A survey published in May 2004 by the National Center for Complementary 
andAlternative Medicine focused on who used complementary and alternativemedicines 
(CAM), what was used, and why it was used. The survey was limited to adults, aged 18 years 
and over during 2002, living in the United States. According to the survey, herbal therapy, or 
use of natural products other than vitamins and minerals, was the most regularly used CAM 
therapy (18.9%) when all use of prayer was excluded
3
. 
 
 Herbal remedies are very common in Europe. In Germany, herbal medications are 
dispensed by apothecaries (e.g., Apotheke). Prescription drugs are sold alongside essential 
oils, herbal extracts, or herbal teas. Herbal remedies are seen by some as a treatment to be 
preferred to pure medical compounds which have been industrially produced 
 
. 
 
 
 
1.3.Traditional herbal medicine system 
Native Americans medically used about 2,500 of the approximately 20,000 plant species 
that are native to North America. 
 
Some researchers skilled in both western and traditional Chinese remedieshave attempted to 
deconstruct ancient medical texts in the light of modern science. This interpretation is 
supported by several investigations of the ORAC ratings of various yin and yang herbs. 
 
In India, Ayurvedic medicine has quite complex formulas with 30 or more constituents, 
including a sizable number of ingredients that have undergone "alchemical processing", 
chosen to balance "Vata", "Pitta" or "Kapha". 
 
In Tamil Nadu, people have their own medicinal system now popularly called 
Siddhamedicine. The Siddha system is entirely in the Tamil language. It contains roughly 
300,000 verses covering various aspects of medicine. This work includes herbal, mineral 
and metallic compositions used as medicine. Ayurveda is in Sanskrit, but Sanskrit was not 
generally used as a mother tongue and hence its medicines are mostly taken from Siddha and 
other local traditions. 
 
MODERN HERBAL 
MEDICINE 
TRADITIONAL HERBAL 
MEDICINE 
HERBAL MEDICINE 
SYSTEM 
1.4.Modern herbal medicine 
 
Many of the pharmaceuticals currently accessible to physicians have a long history of use as 
herbal remedies, including opium, aspirin, digitalis, and quinine. According to theWorld 
Health Organization, approximately 25% of modern drugs used in the United States have 
been derived from plants. At least 7,000 medical compounds in the modern pharmacopoeia 
are obtained from plants among the 120 active compounds currently derived from the higher 
plants and widely used in modern medicine today, 80 percent show a positive correlation 
between their modern therapeutic use and the traditional usage of the plants from which they 
are derived
4 
1.5.Herbal preparations& Safety of Herbal Medicines 
 There are many forms in which herbs can be administered, the most common of 
which is in the form of a liquid that is drunk by the patient either an herbal tea or a (possibly 
diluted) plant extract. Whole herb consumption is also practiced either fresh, in dried form or 
as fresh juice. 
 Several standardization methods may be determining the amount of herbs used. One 
is the ratio of raw materials to solvent. However different specimens of even the same plant 
species may vary in chemical content. For this reason, thin layer chromatography is 
sometimes used by growers to assess the content of their products before use. Another 
method is standardization on a signal chemical
5
. 
 
Safety of Herbal Medicines 
A number of herbs are believed to be likely to cause adverse effects. Additionally 
"adulteration, unsuitable formulation, or lack of study on plant and drug interactions have 
caused to adverse reactions that are sometimes life threatening or lethal. Proper double-blind 
clinical trials are needed to decide the safety and efficacy of each plant before they can be 
recommended for medical use. Although many consumers trust that herbal medicines are safe 
because they are "natural", herbal medicines and synthetic drugs may interact, causing 
toxicity to the patient. 
Standardization of purity and dosage is not authorized in the United States, but even 
products made to the same specification may differ as a result of biochemical variations 
within a species of plant. Plants have chemical defense mechanisms against predatorsthat 
can have adverse or lethal effects on humans.  
Examples of extremely toxic herbs include poison hemlock and nightshade. They are not 
marketed to the public as herbs, because the risks are well recognized, partly due to a long 
and colorful history in Europe, associated with "sorcery", "magic" and intrigue. Although 
not common, adverse reactions have been reported for herbs in extensive usage. On 
circumstance serious untoward outcomes have been related to herb ingestion. A case of 
major potassium depletion has been attributed to chronic licorice ingestion. And 
consequently professional herbalists avoid the use of licorice where they recognize that this 
may be a risk. Black cohosh has been concerned in a case of liver failure. Few studies are 
available on the safety of herbs for pregnant women and one study found that use of 
complementary and alternative remedies are associated with a 30% lower ongoing 
pregnancy and live birth rate during fertility treatment. Examples of herbal therapies with 
likely cause-effect relationships with adverse events include aconite, which is often a legally 
restricted herb, ayurvedic medicines, broom, chaparral, Chinese herb mixtures, comfrey, 
herbscomprising certain flavonoids, germander, guar gum, liquorice root, and pennyroyal.
6 
 
2. LITERATURE REVIEW 
2.1.URINARY SYSTEM INTRODUCTION 
 The Urinary System is a group of organs in the body filtering out excess fluid and 
other substances from the bloodstream. The elements are filtered out from the body through 
urination.. Urine is produced by the kidneys, accumulatedin the bladder and defecated 
through the urethra. Urine is used to remove excess minerals or vitamins as well as blood 
corpuscles from the body. The Urinary system functions with the other systems of the body to 
assist maintaining homeostasis. The kidneys are the main organs of homeostasis because they 
keep the acid base balance and the water salt balance of the blood. 
 
2.2.UROLITHIASIS - INTRODUCTION 
 Stones that are formed within the urinary tract are known as urolithiasis or calculi. 
When crystals are found in urine, oversaturation with the chemical components has 
materialized, but this may have been in vitro, due to temperature or pH variations, so the 
existence of crystalluria alone does not endorse a diagnosis of urolithiasis. Diagnosis can only 
be confirm urolithiasis being identified in freshly voided urine, on radiography, surgery,or 
atultrasound. Radiolucent uroliths and radiodense uroliths less than two millimetres in 
diameter may be difficult to identify on plain radiographs, but the use of double contrast 
methods greatly increases the detection rate. Uroliths may form in the upper or lower urinary 
tract, although clinical signs are usually related with lower urinary tract disease. Many 
animals with radiographic indication of struvite uroliths in the urinary bladder have 
nephroliths as well. 
 
2.3.EPIDEMOLOGY OF UROLITHIASIS 
 The epidemiology of urolithiasis varies according to geographical area in term of 
prevalence and age,incidence, and sex distribution, stone composition and stone location. 
Such differences have been explained in terms of race, diet and climate factors. Socio-
economic conditions have generated difference in the prevalence, incidence and distribution 
for age, sex and type of lithiasis in terms of both the site and the chemical-physical 
composition of the calculi. 
 Epidemiological surveys proves that the prevalence rate ranged between 4% and 20% 
for economically developed countries. 
 Urolithiasis, urinary stone development, is the third most common problem of the 
urinary tract, with lifetime incidence of 12% and 7% in men and women respectively in 
U.S.A. and 34% and 6-9% in women and men respectively in the other western countries
7,8
. 
In Indiaits reversion rate is about 50% in 5-10 years and 75% in 20 years
9,10
. The disease lead 
to loss of about $5 billion per annum in the USA [5]. About 12% of India population are 
suffering from the problem of urinary stones, 50% of which may result in kidney and renal 
injury
11
. About 80% of these calculi are made up of calcium oxalate (CaOx).  
 In the 20
th
 century,occurrence and frequency of upper urinary tract stones were still 
increasing in Western countries probably resulting from developments in clinical-diagnostic 
procedures and differences in nutritional and environmental factors. Endemic infantile 
bladder stone disease, with features similar to those previously defined in Europe in the 
19
th
 century, was fairly prevalent in huge areas of Turkey, Iran, India, China, Indochina and 
Indonesia with stones composed of calcium oxalate and ammonium urate due to malnutrition. 
 
2.4.ETIOLOGY OF UROLITHIASIS 
 Urolithiasis is a heterogeneous disorder, with changing chemical composition and 
pathophysiologic background. Although kidney stones are commonly composed of calcium 
phosphate or calcium oxalate, they may also consist of magnesium-ammonium phosphate, 
uric acid, or cystine. Stones mature from a wide variety of metabolic or environmental 
disturbances, including varying forms of undue hyperoxaluria, urinary acidity, hypocitraturia, 
hypercalciuria,hyperuricosuria, infection with cystinuriaand urease-producing organisms. The 
cause of stone formation may be determined in most patients using the reliable diagnostic 
protocols that are available for the recognition of these abnormalities. Active medical 
treatments, capable of rectifyingessential derangements, have been framed. They comprise 
sodium cellulose phosphate, thiazide, and orthophosphate for hypercalciuric nephrolithiasis; 
acetohydroxamic acid for infection stones; potassium citrate for hypocitraturic calcium 
nephrolithiasis and d-penicillamine and α-mercaptopropionylglycine for cystinuria. Using 
these treatments, new stone development can now be prohibited in most patients
12
. 
 
2.5.TYPES OF KIDNEY STONES 
 
There are four different types of kidney stones. 
Calcium stones 
Most kidney stones are composed of calcium particularly 
calcium oxalate. Calcium phosphate and other minerals also 
may be present. Conditions like hyperparathyroidism, 
increase the chance of calcium stones. Increased levels 
of oxalate also improvesthe risk for calcium stones. The 
calcium stone was shown in Figure no. 1.Certain medicines 
may prohibit calcium stones.  
 
 
  
Uric acid stones 
Some kidney stones are made of uric acid, a waste 
byproduct generally passed out from the body via urine. 
You are more probable to have uric acid stones if you 
have: 
 Low urine output. 
 A diet high in animal protein (red meat). 
 An increase alcohol consumption. 
 Gout. 
 Inflammatory bowel disease. 
The uric acid stone was illustrated in Figure no. 2 
Figure no. 1 
Figure no. 2 
Certain medicines may inhibit or dissolve uric acid stones. 
 
Struvite stones 
Some kidney stones are struvite stones. They can also 
be termed as infection stones if they occur 
with kidney or urinary tract infections (UTIs).  
Struvite stonesof kidney stones at times are also 
called staghorn calculi if they developbig 
enough.Struvite stones can be severe, because they are 
regularly large stones and may show up with an 
infection. Medical therapies, including antibiotics and 
elimination of the stone, is usually required for struvite stones. Women are more favorites 
than men because of their higher risk of urinary tract infections. These stones were illustrated 
in Figure no. 3. 
Cystine stones 
Less common are kidney stones made of a chemical called 
cystine. Cystine stones (illustrated in Figure no. 4) are more 
likely tohappenpeople whose families have a condition that 
results in too much cystine in the urine (cystinuria). 
Cystine stones may be dissolved or prevented with medicine. 
But this may be difficult and not very effective. If a stone 
causes obstruction in the urinary tract or is too large, then it 
willneed to be removed
13
. 
 
 
2.6.CAUSES OF KIDNEY STONES 
 The important cause of kidney stones is a deficiencyof water in the body. Stones are 
more normally found in individuals who consume less than the suggested eight to ten glasses 
of water a day
14
. 
 When there is not sufficient water to dilute the uric acid (a component of urine), the 
urine becomes more acidic. An extremely acidic environment in urine is favorable to the 
formation of renal stones. Medical conditions such as urinary tract infections, Crohn's 
disease, renal tubular acidosis, medullary sponge kidney, hyperparathyroidism,and Dent's 
Figure no. 3 
Figure no. 4 
disease increase the threat of kidney stones. 
Causes of Calcium stones 
 Kidney stones are common, affecting as many as 15 percent of people. These stones 
come in different varieties, with the majority of them including a calcium component. 
Calcium oxalate stones are the most common type and represent 56 to 80 percent of cases in 
adults. Understanding what causes these types of kidney stones can help you prevent them. 
 Kidney Stones Form Crystals in the urine all the time. They are usually small and 
passed painlessly. Kidney stones form when conditions allow these crystals to grow in size. 
In particular, excessive amounts of calcium, oxalate, phosphate, uric acid or cystine in the 
urine can lead to kidney stones. Substances exist normally in urine that can prevent kidney 
stones from developing. Magnesium, citrate, pyrophosphate and other enzymes all act in the 
body as a deterrent to crystals forming and attaching to the surface of kidney tubes. Having 
too little of these substances present in urine can trigger kidney stones
15
. 
 
2.7.FACTOR’S INDUCING LITH’S FORMATION 
 
High levels of calcium 
 Too much calcium in the urine -- hypercalciuria -- can be a risk factor for kidney 
stones and is frequently genetically determined. Certain medications such as calcium-
containing antacids, loop diuretics and glucocorticoids can increase calcium secretion into the 
urine. Too much vitamin D can also lead to increased calcium. Hyperparathyroidism occurs 
when too much parathyroid hormone is produced by the body, causing calcium to be pulled 
from the bones into the blood and subsequently into the urine
16
. This helps to explain the 
association between kidney stones and low bone density. Kidney disease, too, can cause high 
calcium levels in the urine when calcium is not properly absorbed back into the bloodstream. 
High blood pressure and obesity have also been associated with hypercalciuria. 
 
High levels of oxalates 
 Some people are born with a genetic tendency to secrete excess oxalate into the urine. 
This condition, hyperoxaluria, is rare; most cases of hyperoxaluria arise from other causes. 
For one, diets rich in oxalate may place someone at risk for kidney stones. Oxalate-rich foods 
include beets, chocolate, nuts, rhubarb, spinach, strawberries, tea and wheat bran. Excessive 
amounts of vitamin C can also increase oxalate levels, as can inflammatory bowel disease
17
. 
 High levels of Protein 
 High amounts of dietary protein can lead to increases in both calcium and oxalate 
levels in the urine. The elevated protein results in lower urine pH -- an acidic environment 
that makes it easier for calcium oxalate kidney stones to form. It also decreases citrate levels 
in the urine that help prevent kidney stones from forming. The risks of kidney stone 
formation can often be minimized by paying close attention to diet and good hydration
18
. If 
you are concerned about kidney stones, speak with a health-care provider who can evaluate 
the type of stones you might have and what dietary changes would be most helpful for you. 
 
Uric acid stones 
 Uric acid stones are the most common cause of radiolucent kidney stones in children. 
Several products of purine metabolism are relatively insoluble and can precipitate when 
urinary pH is low. These include 2- or 8-dihydroxyadenine, adenine, xanthine, and uric acid. 
The crystals of uric acid may initiate calcium oxalate precipitation in metastable urine 
concentrates. The terms gouty nephropathy, urate nephropathy, and uric acid nephropathy are 
used to describe renal insufficiency due to uric acid precipitation within the renal tubules. 
Uric acid urolithiasis or uric acid kidney stones refer to development of a stone or calculus 
composed of significant amounts of urate in the renal pelvis, ureter, or bladder. 
 
2.8.COMPLICATION OF KIDNEY STONES 
 
The list of complications that have been mentioned in various sources for Kidney stones 
includes: 
 Haematuria 
 Renal colic 
 Ureteric obstruction 
 Proteinuria 
 Dysuria 
 Incontinence, urine 
 Abdominal pain 
 Renal failure 
 
 2.9.FACTORS INFLUENCING THE KIDNEY STONES 
 
 There are multiple things that cause the formation of renal calculus. By controlling 
such factors, you can significantly reduce the risk of kidney stones. The reasons that are most 
commonly associated with the formation of stones are: 
 
Obesity: 
 Obesity is the mother of several diseases. In addition, it also causes difficulty in the 
performance of routine life activities. In summer, it becomes unbearable for an obese person 
to go out in heat. Being overweight is one of the foremost reasons which cause stones to 
form. A recent study has revealed that more a person weighs the greater is the risk of 
developing kidney stones. 
 
Hereditary: 
 The threat of kidney stones lies in the DNA of an individual. For some people this 
condition runs in their family. It means they are likely to fall prey to it even after taking all 
the precautionary measures. They are likely to suffer from this condition at some stage in 
their life. 
 
Diet: 
 Diet directly influences the health of each and every individual.  Diet rich in calcium 
and salts can lead to the development of stones in the blood purification plant of your body, 
i.e. the kidney. 
 
 
 
Medication: 
 People taking certain types of medications are also at the risk of forming kidney 
stones. It happens as a side effect of the drugs. Some medications have this as a known side 
effect. The pharmaceutical companies mention this thing in the leaflets. 
 Drinking enough water and taking other necessary precautions is important, when 
taking those medicines. The people experiencing migraine or seizures use Opiramate 
(Topamax). It is one of the drugs which can cause kidney stones. 
 
Supplements: 
 Supplements have become essential in today’s time to keep our bodies healthy. It is 
also a reason why people have to take poor diet which does not contain all the essential 
nutrients. However, you should not take too much of a specific nutrient say calcium or 
Vitamin D. They can result in development of renal calculus. 
 
Medical Conditions: 
 People with certain medical conditions are also at the risk of kidney stones. For 
example, those who are already suffering from gout or Crohn’s disease are at a higher risk. 
They are more likely to develop stones in comparison with an otherwise healthy person
19
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Hydration: 
 Maintaining the hydration of your body is very significant. We all know that 70% of 
our body is comprised of water. If your water intake is sufficient, you can do away with half 
of the diseases and also feel fit and fresh. 
 These reasons increase the risk of kidney stones formation. Thus taking care of all the 
above causes is paramount, for a happy and a healthy life
20
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2.10.MANAGEMENT OF LITHIASIS 
 
 MEDICATION BASED ON THE TYPE OF STONES 
 HERBAL MEDICINES  
 SURGICAL TREATMENTS FOR KIDNEY STONES 
 OTHER KIDNEY STONE THERAPIES 
 
2.10.1.MEDICATION BASED ON THE TYPE OF STONES 
The most commonly used medicine for kidney stones to pass the stones from the ureter are 
 NSAIDs (Non-steroidal anti-inflammatory drugs) 
 Alpha blockers  
 
Calcium stones 
 Calcium stones are the most regular kind of kidney stone. To avoid them, 
 Thiazides, Orthophosphateand Potassium citrate were used. 
Uric acid stones 
Some renal stones are made of uric acid, a waste product that usually exits the body in the 
urine. To avoid these types of stones,  
Potassium citrate, Allopurinol, and sodium bicarbonate were used. 
Cystine stones 
A very minor number of stones are made of a chemical called cystine. Medications to prevent 
them include: Penicillamine, Tiopronin andPotassium citrate 
 
 
 
Struvite stones 
 Struvite stones (staghorn calculi) are because of recurrent kidney infections. 
Antibiotics are used to treat the infection and help to avoid new stones from development. 
Surgery can be done to exclude the stone. Urease inhibitors are used to prevent struvite 
stones
21
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Table : 1. ANTI-UROLITHIATIC DRUGS 
Name of medication What it’s for Genaeral information 
Thiazide Calcium reduction This reduces the amount of 
calcium in urine and 
prevents calcium stones 
Sodium cellulose phosphate Calcium reduction Binds calcium in the 
intestine and prevents it 
from leaking into the urine 
Oral calcium supplement Reduces oxalate in the body Prevents absorption of 
oxalate in to body 
Allupurinol Uric acid reduction Reduces uric acid in urine 
Polycitra K Uric Acid reduction Prevents uric acid 
Crystallizing in urine 
` 
Allopurinol 
Allopurinol is a xanthine oxidase inhibitor, prescribed for gout. It is used for the treatment of 
high uric acid levels in the urine or blood caused by certain types of cancer chemotherapy. 
 
 
Trade Names: 
Allopurinol (100mg) | Allgout (100mg) |Aloric (100mg) | Lodiric (100mg) |Algor (100mg) | 
Dynol (100mg) | Myloric (100mg) | Allgoric (100mg)| Kayloric (100mg)  Estinol (100mg) 
Potassium Citrate 
Potassium Citrate is an urinary alkalinizing remedy, prescribed for kidney stones. 
 
Trade Names: 
Lasertrate (1100mg/375mg) | Ston-1 (1100mg/375mg/5mL)Ston-1 | (1100mg/375mg/5mL) | 
Ston-1B6 (1100mg/375mg/20mg) | Ston-1B6 (1100mg/375mg/20mg) | BIO-D3 DSSton-1B6 
(714.9mg/263.1mg/15mg) 
 
Tamsulosin 
Tamsulosin belongs to alpha blocker, prescribed for benign prostatic hyperplasia (BPH) or 
prostate enlargement. It increases the flow of urine by soothingthe muscles of the prostate 
and the lower part of the bladder. 
 
Trade Names: 
Veltam (0.2mg) | Flodart | Urimax 0.4 | Gotam | Ubimax (0.4mg) | Uritin | Prostulin (0.4mg) | 
Veltam (0.4mg) | Tamsin |Prostulin (0.2mg)  
 
Tiopronin 
Tiopronin is a chelating agent, prescribed for averting kidney stone formation. 
 
2.10.2.HERBAL MEDICINES  
 
In the therapy of kidney stones, herbs can be used to disrupt them down and avoid their 
development in the first place. Herbs can also boost the flow of urine and comfort the 
irritated walls of the urinary tract. Gravelroot has been used as a treatment to dissolve renal 
stones. The root is usually taken in decoction or tincture base. Hydrangea, madder, and rumex 
can also assistinbreaking up of renal stones
94
. Aloe vera juice may remove stones and prevent 
new ones from development. 
Other herbs, such as couch grassand cornsilk, can relax the walls of the urinary tract. Juniper 
berries are often used to cure urinary tract infections, can be included in a herbal treatment for 
stones
22
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2.10.3.SURGICAL TREATMENTS FOR KIDNEY STONES 
 
Laser Surgery  
If a kidney stone does not step through the ureter within 30 days, surgery is necessary. 
Urologists use several procedures to break up, remove or bypass kidney stones. 
Ureteroscopy  
This procedurecan be used to remove or break up (fragment) stones located in the ureter. A 
special telescopic devicelooks like a long, thin telescope (ureteroscope) is introduced through 
the urethra and moved through the bladder and up the ureter to the stone. Once the stone is 
located, the urologist either removes it with a small basket introduced through the 
ureteroscope (called basket extraction) or breaks the stone with a laser or related device. 
Ureteroscopy is done under general or regional anesthesia on an outpatient basis. 
 
 
 
Lithotripsy  
This methodis most operative for stones in the kidney or upper ureter. Lithrotripsy uses an 
instrument, machine, or probe to breakthe stone into tiny particles that can pass naturally. 
This technique is not suitable for patients with very large stones or other medical conditions. 
 
Ultrasonic lithotripsy 
This technique uses high frequency sound waves supplied through an electronic probe 
presented into the ureter to disrupt up the kidney stone. The fragments are passed by the 
patient or removed surgically. 
 
Electrohydraulic lithotripsy (EHL) 
This technique involves a flexible probe to disrupt small stones with shock waves produced 
by electricity. The probe is located close to the stone through a flexible ureteroscope. 
Fragments can be passed by the patient or extracted. EHL involves general anesthesia and can 
be used to disrupt stones anywhere in the urinary system
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Extracorporeal shock wave lithotripsy (ESWL) 
This technique includes highly focused impulses projected and focused from outside the body 
to pulverize kidney stones anywhere in the urinary system. The stone usually is reduced to 
sand-like granules that can be moved out through patient's urine. Large stones may require 
numerous ESWL treatments. The technique should not generally be used for struvite stones, 
stones over 1 inch in diameter, or in pregnant women. Patients undergoing lithotripsy are 
given a sedative and general or regional anesthesia, and the procedure time takes over an 
hour.  
 
 
Percutaneous Nephrostolithotomy (PCN)  
This surgical technique is done under local anesthesia and intravenous sedation. A guidewire 
and needle are used to access the inside of the kidney. The surgeon then threads various 
catheters over the guidewire into the kidney and operates surgical instruments through the 
catheters to fragment and exclude the kidney stones. This technique achieves a better stone-
free outcome in the treatment of medium and large stones than shock wave lithrotripsy. The 
procedure usually needs hospitalization, and most patients resume normal activity within 2 
weeks. 
Ureteroscopic  
This procedure is done under general anesthesia to treat stones located in the middle and 
lower ureter. A small, fiberoptic device (ureteroscope) is passed through the urethra and 
bladder and into the ureter. Small stones are removed and large stones are shattered using a 
laser or similar device. A small tube (or stent) may be left in the ureter for a few days after 
treatment to promote healing and prevent blockage from fragments, swelling or spasm. 
Open Surgery to Treat Kidney Stones 
This procedure needs general anesthesia. An incision is made in the patient's back and the 
stone is removed through a cut in the ureter or kidney. Most patients need prolonged 
hospitalization and recovery takes numerous weeks. This practice is now rarely used for 
kidney stones
25
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2.10.4..Other Kidney Stone Therapies 
Ayurvedic remedies for Kidney Stones -- Typical kidney stone therapy involves dietary 
alterations and herbal therapy. 
Bodywork for Kidney Stones -- Reflexology is a technique of bodywork that can stimulate 
the organs and regulate bodily functions. Treatment can focus on the responses of the thyroid, 
pituitary gland, and parathyroid glands, spleen, and kidney, among others. 
Homeopathy for Renal Stones -- Common therapies can include berberis, magnesia 
phosphorica and sarsaparilla. 
Hydrotherapy for Kidney Stones --Therapies, such as lukewarm sitz baths, can be used to get 
rid of the pain of kidney stones
26
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2.11.DIAGNOSIS OF LITHIASIS 
 
The various diagnosis test used to determine kidney stones are 
Bloodtesting-Blood tests may expose too much calcium or uric acid in blood. Blood test 
results help screen the health of kidneys. 
Urinetesting- The 24-hour urine collection test may show that excreting too many stone-
developing minerals or too few stone-avoiding substances. For this test, two urine collections 
over two successive days were essential. 
Imaging- Imaging tests may be used to show kidney stones in your urinary tract. Options 
range from simple abdominal X-rays, which can miss small kidney stones, to high-speed or 
dual energy computerized tomography (CT) that may expose even tiny stones. Other imaging 
techniques include an ultrasound, a noninvasive test, and intravenous urography, which 
includes injecting dye into an arm vein and taking X-rays (intravenous pyelogram) or 
attaining CT images (CT urogram) as the dye travels through your kidneys and bladder. 
 
 
2.12.SYMPTOMS OF LITHIASIS 
 
 causes an infection 
 kidney stones can cause pain as they try to pass through 
 A persistent ache in the lower back, which is sometimes also felt in the groin ,  men 
may have pain in their testicles and scrotum 
 nausea (feeling sick) 
 A periods of intense pain in the back or side of your abdomen, or occasionally in your 
groin, which may last for minutes or hours 
 pain when you urinate (dysuria) 
 feeling restless and unable to lie still 
 needing to urinate more often than normal 
 blood in your urine (haematuria)  this may be caused by the stone scratching the 
kidney or ureter 
 
The symptoms of a kidney infection are similar to symptoms of kidney stones, but may also 
include: 
 chills and shivering 
 A high temperature (fever) of 38C (100.4F)  
 diarrhoea 
 feeling very weak or tired 
 cloudy and bad-smelling urine 
 
2.13.PROPHYLACTIC MEASURES 
 
The best way of avoiding kidney stones is to drink sufficient of water each day to prevent 
becoming dehydrated. Keeping urine diluted aids to stop waste products getting too 
concentrated and developing stones. Urine is generally a dark yellow colour in the morning 
because it comprises a build-up of waste products from the body which has produced 
overnight. Drinks such as coffee,tea, and fruit juice can count towards fluid consumption, but 
water is the healthiest choice and is best for avoiding kidney stones formation
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. 
Diet :If kidney stone is produced by too much calcium, it is advisable to decrease the amount 
of oxalates in diet. 
Oxalates avoid calcium being absorbed from the body, and can gather in kidney to develop a 
stone
88
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Foods that includes oxalates: 
 asparagus 
 berries 
 beetroot 
 celery 
 chocolate 
 rhubarb 
 leeks 
 parsley 
 soy products 
 almonds, peanuts and cashew nuts 
 grains, such as oatmeal, wheat germ and wholewheat 
 
2.14.PATHOPHYSIOLOGY OF CALCIUM OXALATE STONE 
FORMATION 
PHYSIOLOGY 
Recent studies using papillary biopsies of stone formers have provided a view of the 
histology of renal crystal deposition which suggests that the early sequence of events leading 
to stone formation differs greatly, depending on the type of stone and on the urine chemistry 
leading to supersaturation
90
.  
Three general pathways for kidney stone formation are seen:  
(1) Stones fixed to the surface of a renal papilla at sites of interstitial apatite plaque (termed 
Randall’s plaque), as seen in idiopathic calcium oxalate stone formers
27
;  
(2) Stones attached to plugs protruding from the openings of ducts of Bellini, as seen in 
hyperoxaluria and distal tubular acidosis; and  
(3) Stones forming in free solution in the renal collection 
system, as in cystinuria
91
.  
The presence of hydroxyapatite crystals in either the 
interstitial or tubule compartment (and sometimes both) of 
the renal medulla in stone formers is the rule and has 
Figure  No.5 
implications for the initial steps of stone formation and the Location of staghorn and non-
staghorn kidney stones. 
Staghorn stones fill various amounts of the renal collection system.  
Non-staghorn stones can be very variable in size and can be found in a major or minor calyx, 
in the renal pelvis or at different sites along the ureters (proximal, middle or distal)
28
.  
Stones can also be found in the urinary bladder 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PATHOPHYSIOLOGY OF LITHI’S FORMATION 
Mechanism of stone formation
66
 
Age Profession Nutrition Climate Inheritance 
Sex Mentality Constitutions Race ------- 
↓ 
Abnormal renal 
morphology 
Disturbed  urine flow 
Urinary tract 
infection 
Metabolic 
Abnormalities   
Genetic Factors 
↓ 
Increased excretion stone forming constituents Decreased excretion of inhibitors of 
Crystallizations  
↓ 
↓ 
Abnormal crystalluria 
Crystals aggregation 
Crystal growth 
↓ 
Formation of stone 
 
 
 
Physico-chemical change in the State of supersaturation 
Hypotheses of stone formation and growth 
Fixed and free particle theories  
Kidney stone development is thought to require the formation of crystals in the tubular fluid, 
followed by crystal retention and accumulation in the kidney 
29
. 
Three pathways of stone formation and growth are currently being investigated . 
The first hypothesis, termed the free particle model, states that crystal nuclei form by 
homogeneous nucleation in the lumen of the nephron under conditions of a phase change 
(increasing supersaturation) in the dissolved salts present in the ultrafiltrate 
30
. Subsequently, 
these nuclei would grow in size and eventually lodge (be retained) in the lumen of the distal 
nephron, causing obstruction of that tubular segment. Obviously, free particle formation 
could occur in the renal collection system at the level of the minor calyx
92
. 
The second hypothesis, termed the fixed particle model, also requires crystal nuclei to form in 
the lumen of the nephron, and then adhere to the apical surface of the tubular epithelium 
31
. 
While a number of mechanisms have been proposed to model this crystal–cell attachment 
step, the most commonly cited model requires renal cell injury, probably as a result of high 
tubular oxalate levels 
32
. Once the crystal–cell attachment step has occurred, the crystal 
nuclei would be fixed in position and exposed to the potentially supersaturated ultrafiltrate 
that would facilitate further growth of these crystals. 
 Both these theories could result in the plugging of the nephron and lead to intratubular 
calcification, termed tubular nephrocalcinosis 
33
. Randall, in his historic paper in 1940, 
described intraluminal calcification (papillary lesion type II) or nephrocalcinosis in only 23 
cases and compared it to the more common finding (204 cases) of interstitial plaque 
(papillary lesion type I), placing the type II lesion in a category different from that of type I 
34
.  
 
We have shown that, in patients who form brushite stones 
35
, or who form apatite 
[hydroxyapatite, Ca5(PO4)3(OH)] stones because of distal renal tubular acidosis (dRTA) 
36
, or 
patients with calcium oxalate stone due to obesity bypass procedures 
37
, or patients with 
cystinuria 
38
, their inner medullary collecting ducts (IMCDs) are plugged (tubular 
nephrocalcinosis) with cystine, which leads to total destruction of the lining cells and focal 
sites of interstitial fibrosis. However, it is unclear how the free or fixed particle hypotheses 
could lead to clinical stone formation (i.e. a stone in the renal pelvis large enough to obstruct 
the ureter), except that either the free or fixed particle process, or both, are occurring in the  
lumen of the ducts of Bellini and/or in the renal pelvis. 
Schematic representation of stone development in 
idiopathic calcium oxalate stone formers. The sequence of 
steps are as follows: 1 apatite deposits develop in the 
basement membrane of the thin loops of Henle; 2 these 
apatite deposits further extends. 
 
  Figure No.6 
The pathogenesis of calcium oxalate stone formation is a multi-step process and in essence 
includes – nucleation, crystal growth, crystal aggregation and crystal retention. Various 
substances in the body have an effect on one or more of the above stone forming processes, 
thereby influencing a person's ability to promote or prevent stone formation93.  
Promoters of stone formation facilitate stone formation whilst inhibitors prevent it.  
 Low urine volumelow urine pH 
 Calcium 
 Sodium 
 Oxalate and  
 urate  
Many inorganic (eg.Citrate, magnesium) and organic (eg. Urinary prothrombin fragment 1, 
glycosaminoglycans, osteopontin) substances are known to inhibit stone formation. 
Organic inhibitory compounds adsorb to the surface of the crystal, thereby inhibiting crystal 
growth and nucleation. This review presents a comprehensive account of the basic principles 
of stone formation and role of urinary inhibitors/promoters in calcium oxalate 
crystallisation.63 
2.15.MODES OF STONE GROWTH 
The modes and putative sites of stone formation are depicted in Figure 6. 
Nucleation 
Nucleation is the process by which free ions in solution associate into microscopic particles. 
Crystallization can occur in solution micro-environments, such as may be present in certain 
points in the nephron 
64
, as well as on surfaces, such as those of cells and on extracellular 
matrix 
68
. There is considerable dispute about the importance of free solution crystallization 
versus crystallization at other sites, in renal tubules or on bladder walls, on normal or 
damaged cells, on areas denuded of cells by certain forms of injury, or at interstitial sites.
69 
Aggregation 
Aggregation is a process by which there is agglomeration of crystals that form in free 
solution into larger multicomponent particles. It may also encompass the phenomenon of 
secondary nucleation of new crystals on the surface of those already formed. The structure of 
stones suggests that one or other of these processes must occur for the stone to grow to a 
clinically significant size.
70
 Kidney stones can be thought of as being similar to concrete, a 
mixture of a binding agent (cement), and particulates such as sand, pebbles, or glass. Stones 
are an aggregation of crystals and an organic matrix, the latter serving as the binding agent. 
The organic matrix contains proteins, lipids, polysaccharides, and other cell-derived 
material.
71 
Crystal growth 
Growth of microscopic crystals is accomplished by movement of ions out of solution onto the 
growing crystal. While some growth of nuclear crystals must occur by movement of ions 
from solution, this is clearly a limited process, as giant single crystals of stone constituents 
are not generally observed. It is more likely that stone growth is accomplished through 
aggregation of preformed crystals or secondary nucleation of crystal on the matrix coated 
surface of another
95
. It has been proposed that the growth of these microscopic crystals to the 
extent that they can be retained in the kidney on the basis of size alone cannot occur without 
aggregation or attachment to specific intrarenal structures.
39 
2.16.PROMOTERS OF STONE FORMATION 
Promoters can increase crystallization of stone constituents or their growth by a number of 
mechanisms. The saturation can be raised by increases in concentration of the reactants. 
Substances in urine may be present that lower the formation product, but the formation 
product may also be lowered by a lack of endogenous inhibitors or opposition to their effects 
by defects in their structure or other interfering substances. Excessively low or high urinary 
pH may induce the formation of heterogeneous nucleating substances
65
. 
Uric acid or urate 
Monosodium urate appears to directly reduce the formation product for calcium oxalate.
40
 
The mechanism for this effect is likely through its antagonistic effecV t to substances in the 
urine that raise the formation product, specifically that attributable to mucopolysaccharides. 
41
In addition to this effect there may be promotion of heterogeneous nucleation by uric acid 
or monosodium urate and enhancement of the attachment of calcium oxalate to cells.
42 
Urine pH 
Highly acid urine leading to precipitation of uric acid crystals may not only lead to uric acid 
stone disease but may also enhance calcium oxalate crystallization due to heterogeneous 
crystallization, in which one type of crystal acts as a template, thereby promoting 
crystallization of a second type of crystal, as noted above.
43
 Highly alkaline urine may also 
promote secondary nucleation of calcium oxalate by precipitation of calcium phosphate.
44 
Low pH cannot really be said to promote crystallization of cystine, as the solubility of this 
substance is minimal at most usual urinary pH values. On the other hand, the solubility of this 
substance, increases significantly at pH values in excess of 7.5.
45
 Commercial laboratories 
that market packages of urine stone chemistries consider stone risk to be minimal when urine 
pH is between 5.8–6.2, in one instance, or between 5.5–7.0 in another. 
2.17.INHIBITORS OF STONE FORMATION 
There are at least four types of inhibitors in urine: small organic anions such as citrate, small 
inorganic anions such as pyrophosphates, multivalent metallic cations such as magnesium, or 
macromolecules such as osteopontin and Tamm-Horsfall protein. 
Alkaline pH 
Alkaline pH cannot be said to be an inhibitor of stone formation, as it has both beneficial and 
deleterious effects depending on the stone constituent under consideration, however alkaline 
pH inhibits cystine and uric acid stone formation, which tend to form in acidic urine, as noted 
above. 
Citrate 
Citrate can be said to be an inhibitor of stone formation. It has several effects. It will lower 
saturation of calcium oxalate by virtue of forming complexes with calcium. When studies are 
performed in which free calcium is controlled, it appears to have an independent effect of 
nucleation and growth (unpublished observations). However, it has also been shown to inhibit 
aggregation of preformed crystals as well as attachment of crystals to urinary epithelium.
46 
Pyrophosphate 
Pyrophosphate, a naturally occurring substance in urine, has been demonstrated to inhibit 
both calcium oxalate and calcium phosphate crystallization. It was found that the average 
urine pyrophosphate concentration was sufficient to significantly inhibit crystal growth. 
47
 
This agent has given discordant results on tests of aggregation and crystal attachment to 
epithelia.
48 
Phytate 
Phytate (myo-inositol hexakisphosphate), a natural compound formed during maturation of 
plant seeds and grains is a common constituent of plant-derived foods. In an animal model, 
calcification in renal tissue was induced in hypercalcemic, hypertensive, male Wistar rats that 
were fed a purified phytate-free diet.
49
 On this diet rats developed significant calcium 
deposits in kidneys and papillae, as well as in kidney tubules and vessels, whereas calcium 
deposits were absent in control and phytate treated rats. Fragments of hydroxyapatite (HAP) 
calculi exhibited the capacity to induce the growth of calcium salts on their surfaces, however 
1.5 mg/L phytate in the synthetic urine utilized in the study inhibited the formation of 
calcium oxalate monohydrate on HAP renal calculi fragments under when calcium 
concentration were in the range considered normal. These findings show that the action of 
phytate as a crystallization inhibitor takes place both in the intrapapillary tissue and urine
50
. 
Magnesium 
Magnesium has also been demonstrated to inhibit stone formation by inhibition of growth 
(and presumably nucleation) of crystals as well as aggregation. Inhibition of crystal 
attachment of calcium oxalate appears to require supra-physiologic concentrations.
51
 Stone 
formation in vitamin B6-deficient animals has been attributed to magnesium depletion, as it is 
ameliorated by magnesium repletion.
52
However, magnesium supplementation for stone 
prevention in humans has had disappointing results.
53 
Glycoproteins 
The effects of the small amount of proteins and glycosaminoglycans present in urine are more 
complex. A number of them are found preferentially in stone matrix, specifically, 
osteopontin/uropontin, Tamm-Horsfall protein, urinary prothrombin fragment 1, and some 
subunits of the serum inter-α-inhibitor. As noted earlier, some of these substances may act as 
attachment sites—hence promoters—when expressed on the surface of cells. As will be 
explained below, the physico-chemical state of these substances may also determine whether 
they act as inhibitors of stone formation processes or promoters. Finally, it is to be expected 
that proteomic analysis of stone matrix may reveal other stone matrix components involved 
in stone formation, however, to date there are little published data
54
. 
Osteopontin/uropontin 
Osteopontin/uropontin inhibits spontaneous nucleation from metastable solutions as well as 
the growth of preformed crystals in a seed growth assay.
55
 The intact molecule and several 
regions associated with both acidic amino acid residues and phosphorylation slows crystal 
growth in seeded assay systems and the intact molecule inhibits attachment to cells, at least in 
some reports.
56
 Others have provided evidence that osteopontin/uropontin bound to the 
surface of cells may enhance attachment.
56
 And finally, calcium oxalate aggregation 
inhibition by osteopontin in vitro can be switched to aggregation promotion by neutralization 
of its net negative charge by poly-arginine.
57
 
 
 
 
  
 
 
 
 
3.OBJECTIVE OF THE STUDY 
The problem of urinary stone or calculi is a very ancient one  . The stones form in all parts of 
the urinary tract , the kidneys, the ureters and in bladders and they may vary in size 
considerably . 
Majority of calculi are made up of Calcium oxalate, calcium phosphate, uric acid or 
magnesium ammonium phosphate. In India the common components of urinary calculi is 
calcium oxalate. A number of vegetable drugs have been used in India and elsewhereand gain 
efficient cure of urinary stones
58
. 
There are several options available in the management of ureteral stones. Treatment depends 
upon the size of the stones, composition and associated morbidity, physician skill, patient 
health ,preference and finally costs
59 
Many remedies have been employed during the ages for treating urolithiasis. Most of the 
remedies were taken from plants proved to be useful, though the rational behind their use is 
not scientifically established except for a few plants and some proprietary composite herbal 
drugs.
60 
3.1.SCOPE AND PLAN OF WORK 
3.1 Scope of work 
Recently there has been increasing interest in use of traditional medicine .In many countries 
trditional medicines used for controlling kidney disorders significantly there is a increase in 
occurrence of kidney stones in recent years.Therefor they look for more effective and  safer 
antiurolithiatic agents 
Estimated life time risk of 2%-5% in Asia , 8%-15% in Europe and America and around 20% 
in Middle East it is associated with a high risk of re-occurence .Nephrolithiasis is a frequent 
disease that affects about 10% of people in western countries. The prevalence of calcium 
oxalate stones has been constantly increasing during the past fifty years Stone composition 
varies depending to gender and age of patients and also underlines the role of other risk 
factors and associated pathologies such as body mass index and diabetes mellitus.A high 
prevalence of uric acid was found in overweight and obese stone formers and in diabetic ones 
as well. Another important finding was the increased occurrence with time of calcium oxalate 
stones formed from papillary Randall's plaques, especially in young patients. Nutritional risk 
factors for stone disease are well known: they include excessive consumption of animal 
proteins, sodium chloride and rapidly absorbed glucides, and insufficient dietary intake of 
fruits and potassium-rich vegetables, which provide an alkaline load. As a consequence, an 
excessive production of hydrogen ions may induce several urinary disorders including low 
urine pH, high urine calcium and uric acid excretion and low urine citrate excretion.
76
 Excess 
in calorie intake, high chocolate consumption inducing hyperoxaluria and low water intake 
are other factors, which favour excessive urine concentration of solutes. Restoring the dietary 
balance is the first advice to prevent stone recurrence. However, the striking increase of some 
types of calculi, such as calcium oxalate stones developed from Randall's plaque, should alert 
to peculiar lithogenetic risk factors and suggests that specific advices should be given to 
prevent stone formation. 
Urolithiasis is a global problem , successful treatment is very important for preventing or 
atleast delaying the onset of long term complications. When compared to that of the 
synthetically derived drugs , medicines derived from the natural medicinal plants possess 
lesser side effects .Therefore the search for safer and more effective antiurolithiatic agents 
has become an area of active research, it is also believed that the traditional medicine 
attenuate the progression of complications of the disease
77 
Traditionally apium graveolens seeds are used to treat  Kidney stone.The objective of this 
study was to ascertain the scientific basis for the use of this Apium graveolens in the 
management of Kidney stones using ethylene glycol induced urolithiasis in rats . 
Apium graveolens used in the traditional system of medicine in India for the treatment of  
Kidney stones of pharmacologically evaluate the plant for its antinephrolithiatic property 
potential in the present study 
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4.MATERIALS AND METHODS 
4.1.LITERATURE REVIEW OF PLANT 
1.Antinociceptive effects of isolated fractions from Apium 
graveolens seeds  
Mina Ramezani et al. 2009 Jun 12 47(8) 
The antinociceptive effects of the aqueous and hexane extracts obtained from Apium 
graveolens L. (Apiaceae) seeds were evaluated. the hexane fraction reduced the nociception 
produced by formalin solution in the first phase (0-5 min) at 300, 400, and 500 mg/kg BW, 
and in the second phase (20-30 min) at 500 mg/kg BW. It is concluded that the hexane 
fraction has major contribution to the overall antinociceptive activity. Both fractions showed 
remarkable anti-nociceptive effect which supported the traditional use of Apium graveolens 
in diseases associated with inflammation. 
2.The Anti-inflammatory Activity of Celery Apium graveolens L. 
(Fam. Umbelliferae) 
 
DA Lewis et al. 2008 Sep 27 23(1) 
Aqueous extracts of celery stem have been investigated and found to have significant anti-
inflammatory activity against two animal models. Celery contained a phytosterol with some 
anti-inflammatory activity but it was concluded that the major anti-inflammatory effect was 
due to unidentified polar substances. Mannitol was also identified in celery but this 
compound did not reduce carrageenan-induced oedema in the rat although the celery fraction 
with anti-inflammatory action was active against this model. Mannitol has been reported to 
reduce inflammation in adjuvant-induced arthritis in the rat. It was concluded that celery stem 
does possess anti-inflammatory properties which may form a basis for the reputation of the 
plant as a medicinal treatment for rheumatic disease. 
3. Hepatoprotective activity of Apium graveolens and Hygrophila 
auriculata against paracetamol and thioacetamide intoxication in 
rats 
Anuba Singh et al. 1995 Dec 15 119-126 
Seeds of Apium graveolens L. (Apiaceae) and Hygrophila auriculata (K. Schum.) Heine 
(Syn. Astercantha auriculata Nees, Acanthaceae) are used in Indian systems of medicine for 
the treatment of liver ailments. The antihepatotoxic effect of methanolic extracts of the seeds 
of these two plants was studied on rat liver damage induced by a single dose of paracetamol 
(3 g/kg p.o.) or thioacetamide (100 mg/kg, s.c.) by monitoring several liver function tests, 
viz. serum transaminases (SGOT and SGPT), alkaline phosphatase, sorbitol dehydrogenase, 
glutamate dehydrogenase and bilirubin in serum. Furthermore, hepatic tissues were processed 
for assay of triglycerides and histopathological alterations simultaneously. A significant 
hepatoprotective activity of the methanolic extract of the seeds of both the plants was 
reported. 
4. In vitro antimicrobial, antioxidant activity and phytochemical 
screening of Apium graveolens. 
 
Zakir Ud Din et al. 2015 Sep 5 Pg-1699-1704 
The present study evaluates the phytochemical screenings, antioxidant activity and 
antimicrobial assay of Apium graveolens L. The phytochemical screening showed the 
presence of flavonoids, tannins, saponins and steroids in Apium graveolens while terpenoids 
was absent. The total phenolic content was slightly higher in methanolic fraction (63.46 ± 
12.00 mg GAE/g) followed by ethanol (36.60 ± 12.28 mg GAE/g) and hexane fractions 
(34.86 ± 6.96 mg GAE/g). The flavonoid content was high in methanolic extract (56.95 ± 
7.14 mg Quorcetin/g) and low level of the content was found in methylated spirit extract 
(29.2 ± 3.15 mg Quercitin/g). Antioxidant activity assayed by FRAP was higher in 
methanolic fraction (12.48 ± 1.06 mmole of FeSO₄equivalent/litre of extract) compared with 
other extracts. Likewise, good antimicrobial activity was measured by crude ethanol fraction 
against S. aureus (MIC=0.12 ± 0.03 μg/ml) and S. typhi (MIC= 0.5 ± 0.2 μg/ml). Results also 
that ethanolic fraction was effective against A. flavus (MIC= 05 ± 1.0 μg/ml). 
5.Vasorelaxant activity of extracts obtained from Apium 
graveolens: Possible source for vasorelaxant molecules isolation 
with potential antihypertensive effect 
Vergara-GaliciaJorgeet al.2013 October 10 Pg 776-779 
To investigate vasorelaxant effect of organic extracts from Apium graveolens (A. 
graveolens) which is a part of a group of plants subjected to pharmacological and 
phytochemical study with the purpose of offering it as an ideal source for obtaining lead 
compounds for designing new therapeutic agents with potential vasorelaxant and 
antihypertensive effects.An ex vivo method was employed to assess the vasorelaxant 
activity. This consisted of using rat aortic rings with and without endothelium precontracted 
with norepinephrine.All extracts caused concentration-dependent relaxation in precontracted 
aortic rings with and without endothelium; the most active extracts were Dichloromethane 
and Ethyl Acetate extracts from A. graveolens. These results suggested that secondary 
metabolites responsible for the vasorelaxant activity belong to a group of compounds of 
medium polarity. Also, our evidence showed that effect induced by dichloromethane and 
ethyl acetate extracts from A. graveolens is mediated probably by calcium antagonism.A. 
graveolens represents an ideal source for obtaining lead compounds for designing new 
therapeutic agents with potential vasorelaxant and antihypertensive effects. 
6.Application of Apium graveolens in treatment of hypertension 
 Gharouni Manocheher et al. 2000 Vol 58 Pg 67-69 
Apium graveolence has an small brown olyptical seed with pharmacological activity. To evaluate it's application 
in treatment of hypertension, 37 hypertensive patients (20 Female, 17 male) with the age range of 45-65 were 
given 6 grams of powder of apium graveolence seed and then the blood pressures before end after the remedy 
were compared. Before treatment, the plean systolic blood pressures was 171/35mlHg and the mean diastolic 
blood pressure was 94 mlHg. After they became 154/3mlHg and 89/6mIHg respectively.The difference of blood 
pressure before and after treatment was statistically significant (P<0.05), so we concluded that apium 
graveolence seed can he used as is a safe and effective treatment for high blood pressure. Further controlled 
studies should be done to compare it with available antihypertensive drugs. 
Part-a 
 Plant Collection and authentication 
 Plant Introduction 
 Sample preparation and extraction 
 List of chemicals used 
 Preliminary phytochemical analysis 
4.2.PLANT COLLECTION AND AUTHENTICATION 
The seeds of Apium graveolens L (apiaceae) were collected from local source, Tamil Nadu 
(Chennai) in the month of March. The seeds were identified and authenticated by Prof. 
P.Jayaraman, Retd Professor of Presidency College and Director of Institute of Herbal 
Science Plant Anatomy Research Centre, West Tambaram, Chennai-600045. A voucher 
specimen was deposited at C.L.Baid Metha College of Pharmacy for future reference.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.PLANT INTRODUCTION 
APIUM GRAVEOLENS 
The scientific name of celery, celery seed is Apium Graveolens. It is also known with the names 
of marsh parsley and wild celery. In Hindi it is called Ajwain ka patta. Celery has been used in 
Chinese medicine since fifth century BC onwards. It is a salad plant. 
In India celery is used in Ayurvedic medicine to relieve flu, colds, poor digestion, water retention, 
disorders of spleen and liver and different types of arthritis. The volatile oil is used in 
pharmaceutical and perfume industries
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.Apium graveolens Linn. (Apiaceae) is commonly 
known as Celery (Norman et al., 2001). In India Celery plant is native in Punjab, Himachal 
Pradesh and Uttar Pradesh states. It is commonly found in foot hills of Himalayas (Pullaiah, 
2006; Nadkarni and Nadkarni, 1976; Singh et al., 1995). 
 
 
Figure No.7 – Apium graveolens seeds 
 
SYNONYMS 
Apium graveolens .var dulce 
Apium graveolens L 
Apium petroselinum Linn 
Apium graveolens .var rapaceum 
 
CHARACTERISTIC OF APIUM GRAVEOLENS 
An erect ,annual or biennial herb with very small seedsCelery plant is thin and grows to a 
height of two to three feet. It has around three to five segmented flowers and leaves. The flowers 
are green-white in colour and the seeds are grayish brown in colour. It is biennial aromatic plant 
which has fleshy bulbous roots. 
 
 
DESCRIPTION 
 It is an erect, annual or biennial herb. The roots are numerous, succulent and well developed. 
The stem branches are angular or fistular, and are conspicuously jointed. The leaves are 
oblong to obovate, pinnate or trifoliolate. The leaflets are ovate to suborbicular and 3-lobed. 
The flowers are white or greenish white and very small. The fruit is a schizocarp consisting 
of two mericarps, sub-orbicular to ellipsoid, greyish brown to brown with pale ridges, 
aromatic and slightly bitter. The seed and flowering shoots
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Figure No. 8 
 
 
 
TAXONOMY 
Domain : Eukaryota 
Kingdom : Plantae 
Phylum : Spermatophyta 
Class : Dicotyledonae 
Order : Apailes 
Family : Apiaceae 
Genus : Apium 
Species : Apium graveolens 
 
VERNACULAR NAMES 
English name : Celery , Ajowan 
Indian : Ajamoda 
Tamil : Seevarikeerai , callari 
Hindi : Shalari 
Arabic : Ajmod 
 
USES 
Internal Use : 
 It is an aromatic bitter herb which reduces blood pressure, relieves indigestion, and 
stimulates the uterus, acts as anti-inflammatory, diuretic and aphrodisiac. 
 Celery contains furocoumarins which are used for its carminative, stomachic, 
emmenagogue and diuretic properties. 
 It is taken internally for relieving rheumatoid arthritis, osteoarthritis, gout and inflamed 
urinary tract. 
 In Ayurveda it is used as a nerve tonic and also to relieve bronchitis and asthma. 
External use : 
 Celery has been used for relieving fungal infections and also tumours. 
Aromatherapy : 
Seeds are used for distilling oil and it is useful in toning the nervous system, relieving cellulite 
and water retention. The essential oil of celery cleanses and purifies the kidneys, liver and spleen. 
It helps to reduce uric acid in the joints of arthritis, rheumatic and gout patients. The puffiness of 
the skin is reduced with the usage of celery essential oil. 
 
ECONOMIC IMPORTANCE 
THIS HERB PROVES HELPFUL IN RELIEVING SEVERAL AILMENTS. SOME 
OF THESE ARE: 
 Cancer: The seeds of celery have cancer fighting abilities. There are some active 
components which are helpful in combating cancer tumours like phthalides and 
polyacetylenes. 
 Blood pressure: Consuming celery seeds everyday will promote optimum levels of blood 
pressure. 
 Liver disorders: Negative effects of acetaminophen are reduced with the usage of celery 
seeds. Liver is protected because of the analgesic properties. 
 Cholesterol: Celery seeds have the ability to lessen cholesterol levels. Herbal 
practitioners advocate the usage of celery seeds for promoting circulatory system. 
 Pain and inflammation: Because of the anti-inflammatory agents in celery, it acts well in 
relieving inflammation and pain of the joints. These seeds work well on ailments like 
rheumatism, gout and arthritis. 
 Muscle spasms: Celery seeds are stimulating in nature and help to ease the uterus muscles 
during menstruation. Women can get relief from menstrual cramps and pains by using 
celery seeds. 
 Kidney problems: Celery seeds are diuretic and hence eliminate excess uric acid from the 
body. These seeds can be consumed by people suffering from gout, water retention and 
kidney stones. 
 Urinary tract infections: Celery seeds have antiseptic and antibiotic properties and can 
be used to relieve urinary tract infections. Patients suffering from bladder ailments, cystitis 
and kidney problems are advised to use celery seeds every day. 
 
PHARMACOLOGICAL ACTIVITIES 
 Celery is said to promote the elimination of uric acid. It is an aromatic bitter herb that 
reduces blood pressure, relieves indigestion, stimulates the uterus and act as anti-
inflammatory (Leung et al., 1980).  
 The ripe seeds, herb and root are uricosuric, nervine, stimulant and tonic (Zheng et al., 
1993; Ko, 1991). 
 An essential oil obtained from the plant has a calming effect on the central nervous 
system 
 Some of its constituents have antispasmodic, sedative and anticonvulsant actions.  
 It has been shown to be of value in treating high blood pressure (Bisset et al., 1994). 
 It is used in treating rheumatism and kidney complaints (Yan et al., 1998).  
 It is considered one of the most alkaline of foods. 
 It has a special affinity for the stomach, kidneys, and liver and helps to neutralize acids in 
the body. 
4.4.SAMPLE PREPARATION AND EXTRACTION 
Apium graveolens seeds were collected and washed with clean water. It was dried at room 
temperature for a week. Then it was powdered using an electronic mixer. The powdered drug 
was extracted by continuous solvent extraction method with Soxhlet apparatus. The ethanolic 
extract was concentrated by solvent evaporation. 5gm of the crude drug sample was taken in 
a extractor tube and a mixture of 50 ml ethanol with 50 ml water was added to it. After the 
completion of 30 cycles the extract was removed. The percentage yield of ethanolic extract of  
Apium graveolens was found to be 7%. The extract was subjected to Hexane for defatting. 
The concentrated crude extracts were stored at 4°C in a refrigerator and used for further study 
 
4.5.LIST OF CHEMICALS USED 
S.NO MATERIAL SOURCE 
1 Ethylene glycol S.d.fine chemicals Ltd. Mumbai 
2 Formalin 10% S.d.fine chemicals Ltd. Mumbai 
3 Chloroform L.R S.d.fine chemicals Ltd. Mumbai 
4 Diethyl ether L.R S.d.fine chemicals Ltd. Mumbai 
5 Ammonium Chloride S.d.fine chemicals Ltd. Mumbai 
6 Ethanol S.d.fine chemicals Ltd. Mumbai 
7 Concentrated HCL S.d.fine chemicals Ltd. Mumbai 
8 Calcium kit S.d.fine chemicals Ltd. Mumbai 
9 Nitric oxide kit S.d.fine chemicals Ltd. Mumbai 
10 Phosphate kit S.d.fine chemicals Ltd. Mumbai 
11 Creatinine kit S.d.fine chemicals Ltd. Mumbai 
12 Thiazide 
Ranbaxy Laboratories Pvt Limited 
N.Delhi 
13 
Ethylene diamine tetra acetic acid 
(EDTA) Disodium Salt Chemspure, Chennai 
14 Hydrogen peroxide Chemspure, Chennai 
15 Distilled water 
Andavar Distilled Water Company, 
Chennai 
16 Sodium hydroxide Chemspure, Chennai 
17 Sodium bicarbonate S.d.fine chemicals Ltd. Mumbai 
4.6.PHYTOCHEMICAL INVESTIGATION 
Materials and methods : 
Chemicals and reagents: 
           Laboratory grade chemicals were used for routine work . Analytical grade reagents  
(A.R) were used for analytical work . 
Preliminary phytochemical screening 
Ethanolic seed extract of apium graveolens were subjected to phytochemical screening for the 
presence or absence of phytoconstituents by the following methods.  
 Test for alkaloids 
The extract was treated with dilute hydrochloric acid and filtered . The filtrate is used in the 
following tests. 
a) Mayer’s reagent (Potassium Mercuric Iodine solution) 
0.5 ml the extract was treated with Mayer’s reagent and the appearance of cream 
colour indicates the presence of alkaloid 
      b) Dragendroff’s test (Potassium Bismuth iodide) 
0.5 ml the extract was treated with Dragendroff’s reagent and the appearance of 
reddish brown  colour indicates the presence of alkaloid 
Test for alkaloids: The extract was treated with dilute hydro chloric acid and filtered. 
The filtrate is used in the following tests. • Mayer’s reagent (Potassium Mercuric 
Iodine Solution) 0.5 ml of the extract was treated with Mayer’s reagent and the 
appearance of cream color indicates the presence of alkaloid • Dragendroff’s test 
(Potassium Bismuth Iodide) 0.5ml of the extract was treated with Dragendroff’s 
reagent and the appearance of reddish brown colour precipitate indicates the presence 
of alkaloid. 
c)Wagner’s test (Iodine-Potassium Iodide Solution) 
 0.5 ml of the extract was treated with Wagner’s test and the appearance of brown 
color precipitate indicates the presence of alkaloid.  
Test for Carbohydrates  
• Molisch’s test  
The extract was treated with 3 ml of alpha-naptholin alcohol and concentrated 
sulphuric acid was added along the sides of the test tube carefully. Formation of violet 
colour ring at the junction of two liquids indicates the presence of carbohydrates. 
 Fehling’s test (CuSO4.7H2O +KOH+ Potassium Tartartes)  
The extract was treated with Fehling’s solution A and B heated in boiling water for 
few minutes. The appearance of reddish brown colour precipitate indicates the 
presence of reducing sugars. 
 • Benedict’s test (Sodium citrate + sodium carbonate + CuSO4.7H2O) 
The extract was treated with Benedict’s test and heated in boiling water for few 
minutes. The appearance of reddish orange colour precipitate indicates the presence of 
reducing sugars. 
Test for steroids  
 Liberamann burchard test  
The extract was treated with small quantity of concentrated sulphuric acid, glacial 
acetic acid and acetic anhydride. The appearance of green colour indicates the 
presence of steroids  
 Salkowsi test  
The extract was treated with chloroform and to that add a drop of concentrated 
sulphuric acid. The appearance of golden yellow colour was obtained.  
Test for proteins  
• Millon’s test  
The extract was treated with Millon’s reagent. The appearance of pink colour 
indicates the presence of proteins.  
Test for Tannins 
Lead acetate test  
a) The extract was treated with 10% lead acetate solution. The appearance of white 
precipitate indicates the presence of tannins 
b) The extract was treated with aqueous bromine solution. The appearance of white 
precipitate indicates the presence of tannins.  
Test for Phenols 
 • Ferric chloride test  
The extract was treated with neutral ferric chloride solution. The appearance of violet 
indicates the presence of phenols.  
 
• Liebermann test 
The extract was treated with sodium nitrite and add a drop of concentrated sulphuric 
acid. The appearance of red colour after turns to black colour was obtained.  
• Lead acetate test 
 The extract was treated with 10 ml water and 5 drops of 1% lead acetate solution was 
added. The appearance of white precipitate was obtained.  
Test for Flavonoids 
5 ml of extract solution was hydrolysed with 10% v/v sulphuric acid and cooled. 
Then, it is extracted with diethyl ether and divided into three portions in three separate 
test tubes.1 ml of diluted sodium carbonate, 1 ml of 0.1N sodium hydroxide, and1ml 
of strong ammonia solution were added to the first, second and third test tubes 
respectively. In each test tube, development of yellow colour demonstrated the 
presence of flavonoids. 
Test for Glycosides 
The extract was dissolved in the glacial acetic acid and few drops of ferric chloride 
solution was added, followed by the addition of concentrated sulphuric acid, 
formation of red ring at the junction of two liquids indicates the presence of 
glycosides 
Test for Saponins 
1ml of the extract was diluted to 20ml with distilled water and shaken well in a test 
tube. The formation of foam in the upper part of the test tube indicates the presence of 
saponins.  
Test for Terpenoids 
The extract was treated with tin and thionyl chloride. The appearance of pink colour 
indicates the presence of terpenoids.. 
Test for sterols  
The extract was treated with 5% potassium hydroxide solution; appearance of pink 
colour indicates the presence of sterols. Test for thiol: The extract is treated with 
ellman reagents A and B. The appearance of yellow colour solution was obtained 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PART –B 
5.Animal Studies 
5.1.Experimental animals 
33 Male Albino Wistar rats (150-350 g) were used in the present experimental study.
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All the 
experimental procedures and protocols used in this study were approved from the 
Institutional Animal Ethics Committee (/IAEC/L/01/CLBMCP/2017).  
The animals were kept in polypropylene cages and maintained under standardized 
conditions (temperature 27°C ± 1°C, humidity 60% ± 4%, and natural lighting), fed 
with a standard diet and water. The rats were divided into five groups, a minimum of 
six animals were used in each group.They were housed five per cage under standard 
laboratory conditions at a room temperature at 22±20C with 12hr light/dark cycle. 
The animals were provided with pellet chow and water. Animals were acclimatized to 
laboratory conditions one week prior to initiation of experiments. Ethical committee 
clearance was obtained from IAEC (Institutional Animal Ethics Committee) of 
CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on 
Animals).  
IAEC Reference no: IAEC//L/01/CLBMCP/2017 
• Species / Common name  :Wistar Albino rats 
• weight    : 150g-350 g 
• Gender    : Male                                                           
30 male animals were used in the study of Nephrolithiasis and 3 female animals were 
used for acute toxicity study 
 
 
 
 
 
Grouping of animals 
 
 
 
 
 
 
 
Experimental Procedure  
30 healthy male adult Wistar rats weighing (200-250g) were divided into 5 groups consisting 
of six animals in each group. Ethylene glycol and ammonium chloride induced urolithiatic 
model in rats was used to assess the effect of ethanolic extract of Apium graveolens. 
Rats were housed in cages for entire duration of the experiment. The urine of each rat was 
collected on the 28th day of the experiment. The estimation of biochemical parameters like 
Urea, creatinine, SGOT, SGPT, Uric acid were carried out. 
Administration of dose 
Stones were induced in rats by giving 0.75% of ethylene glycol and 1% of ammonium 
chloride in 100ml of drinking water per day orally. The inducing agent was administered for 
28 days In the curative study two groups have involved Low dose (200mg/kg) and High dose 
(400mg/kg) all the groups except control, standard and negative control received extract by 
oral route from 15th day till 28th day
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S.NO GROUPING ANIMALS REQUIRED 
1 Group I -CONTROL 6 male Wistar Albino rats 
2 Group II – NEGATIVE 
CONTROL 
6 male Wistar Albino rats 
3 Group III - STANDARD 6 male Wistar Albino rats 
4 GroupIV-LOW DOSE(EEGA 
200mg/kg) 
6 male Wistar Albino rats 
5 GroupV-HIGH DOSE(EEGA 
400mg/kg) 
6 male Wistar Albino rats 
 5.2.ACUTE ORAL TOXICITY STUDY 
 The acute oral toxicity study was carried out as per the guidelines set by the 
organization for economic co-operation and development (OECD) revised draft guidelines 
423B received from the committee for the purpose of control and supervision of experiments 
on animals (CPCSEA), Ministry of social Justice and Empowerment, Government of India . 
 The LD-50 cut-off dose for EtAG of seeds are given in Table 11of the LD 50 dose 
was taken as a therapeutic doseAcute oral toxicity study was performed as per guidelines 
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Albino mice (n = 6) of either sex selected by random sampling technique were used for acute 
toxicity study. The animals were kept fasting overnight providing only water, after which the 
extract (50% ethanolic extract) was administered orally at the dose level of 5 mg/kg body 
weight by gastric intubation and observed for 14 days. If mortality was observed in two out 
of three animals, then the dose administered was assigned as toxic dose. If mortality was 
observed in one animal, then the same dose would be repeated again to confirm the toxic 
dose. If mortality was not observed, the procedure was carried out accordingly. 2000 mg/kg 
body weight was administered. According to the results of the acute toxicity test, the doses 
were chosen for experiments. 
EXPERIMENTAL PROCEDURE 
 Healthy adult wistar albino rats weighing 150-200 grams were used for the study, The 
starting dose level of 2000mg/kg body weight p.o of Apium graveolens was given. Since 
most of the crude extracts possess LD50 value more than 2000 mg/kg, p.o. so starting dose 
2000mg/g p.o. was used. Dose volume administered was 1ml/100 gm body weight to each rat 
which werefasted overnight with water ad libitum. Food was withheld for further 3-4hrs after 
oral administration of drugs and observed for the signs of toxicity. 
 Body weight of each rat before and after administration of Apium graveolens was 
noted and any changes in skin and fur, eyes and mucous membrane, respiratory, circulatory, 
autonomic& central nervous system, motor activity and behavior pattern was observed and 
also sign of tremors, convulsion, salivation, diarrhoea, lethargy, sleep and coma was noted. 
The onset of toxicity and signs of toxicity was also noted. The animals were kept under 
observation for 14 days
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STONE INDUCTION METHOD 
 
Animals receiving 0.75% v/v EG and 1%v/v NH
4
CL was added in drinking water for 28 days 
forming renal calculi composed mainly of calcium oxalate 
 
6.1.Ethylene Glycol : 
 
Structure of ethylene glycol 
 
 
Ethyelene glycol is widely used for kidney stone formation in rats. When ethylene glycol is 
metabolized by the body , it produces three toxic metabolites : Glycoaldehyde, glycolate and 
glyoxylate , these metabolites causes tissue destruction , primarily from calcium oxalate 
crystal deposition, and metabolic abnormalities , speacially a high anion gap metabolic 
acidosis, lactic acidosis and hypocalcemia . Oxalic acid combines with calcium to form 
calcium oxalate crystals, which deposit in the kidneys 
 
The accumulation of Calcium Oxalate Monohydrate(COM)  crystals in kidney tissue 
produces renal tubular necrosis that leads to kidney failure . In vivo models in EG –dosed rats 
have correlated the severity of renal damage with the accumulation  of COM crystals in 
kidney tissue . In cultured kidney cells, including human Proximal tubule (HPT) cells , have 
demonstrated that only the COM crystals , not the oxalae ion, glycoldehyde , or glyoxylate , 
produce a necrotic cell death at toxicologically relevant concentrations. In EG poisoning , 
COM crystals accumulate to higher concentrations in the kidney through the process 
involving adherence to tubular cell membranes , followed by internalization of crystals
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.  
6.2.MECHANISM OF INDUCTION TECHNIQUE 
1. Different chemicals used to induce urolithiasis in experimental animals models by 
using EG, glycolic acid and ammonium oxalate 
2. Animals treated with EG ,it is metabolized in to oxalate particularly in the liver and 
kidney and its harmlessly excreted 
3. Although increase urinary excretion of oxalate (hyperoxaluria) can be toxic largely 
because of its propensity to crystallize and form the CaOx crystal deposition in 
kidney. 
4. CaOx crystals can block the renal tubules , cellular function, and kill nearby cells 
(Randall plaques) 
5. Ingestion of Ammonium chloride with EG can cause the chronic metabolic acidosis 
that is accommodated by urinary acidification (Renal tubular acidosis) theses acidosis 
leads to decrease in excretion of citrate in urine
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6. Hypocitaturia caused raised level of ionized calcium and reduces the inhibitory 
activity against calcium salts . These leads to deposition of CaP crystals in kidney 
7. Composed of CaP and RP seem to provide the platform for CaOx crystals to form 
through heterogenous nucleation and grow in to nephrolithiasis 
6.3.Mechanism of Ethylene glycol Toxicity 
CaOx crystals  alter membrane structure and function , to increase reactive oxygen and to 
produce mitochondrial dysfunction . This process is likely to be involved in the mechanism 
of cell death . Accumulation of COM crystals in the kidney is responsible for producing the 
renal toxicity associated with EG poisoning . The development of a pharmacological 
approach is to reduce CaOx crystal adherence to tubular cells and its cellular interactions 
would be valuable as this would decrease the renal toxicity and also in other hyperoxaluric 
diseases such as primary hyperoxaluria and kidney stone formation
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 5.5.EXPERIMENTAL DESIGN 
Anti-nephrolithiatic activity : Thirty healthy male adult wistar albino rats weighing (150-
200gms) were divided in to 5 groups consisting of 6 animals in each group .Ethylene glycol 
induced urolithiatic model in rats was used to access the effect of ethanolic extract of Apium 
graveolens . The study is designed to find out the effect of ethanolic extracts of Apium 
graveolens on therapeutic usage against ethylene glycol induced nephrolithiasis. 
Rats were housed in cages for entire duration of the experiment .The serum of each group 
was collected for the estimation of bio-chemical parameters. 
Urea, Creatinine, SGOT, SGPT, Uric acid are estimated. Therapeutic groups will be 
sacrificed on 29
th 
day. Right Kidney was examined for the presence of calcium oxalate 
crystals and stone formation by histological techniques.  
Table No:2    Experimental design and treatment plan for the evaluation of nephron 
lithiatic activity in EEAG 
 
 
S.NO STATUS INDUCTION OF 
UROLITHIASIS 
NUMBER OF 
ANIMALS 
TREATMENT 
1 Group I -
Normal 
  --------- 6 male Wistar 
Albino rats 
Vehicle 
2 Group II – 
Negative 
control 
0.75%v/v Ethylene glycol in 
drinking water daily for 28 
days orally 
6 male Wistar 
Albino rats 
Vehicle 
3 Group III – 
Standard drug 
treated  
0.75%v/v Ethylene glycol in 
drinking water daily for 28 
days orally 
6 male Wistar 
Albino rats 
Thiazide 
(0.9mg/kg) from 
15
th
 day to 28
th
 day 
4 Group IV -  Ethylene glycol 
(0.75mg/kg/day, orally)+low 
dose of drug infusion 
6 male Wistar 
Albino rats 
Ethanolic extract of 
seeds (200 mg/kg) 
from 15
th
 day to 
28
th
 day 
5 Group V Ethylene glycol 
(0.75mg/kg/day, orally)+ high 
dose of drug infusion 
6 male Wistar 
Albino rats 
Ethanolic extract of 
seeds (400 mg/kg) 
from 15
th
 day to 
28
th
 day 
7.STUDY PLAN 
7.1.GENERAL PARAMETERS 
1. Measurement of Body weight 
 
The weight (in grams) of the animals was noted on the first and Last day of treatment and the 
percentage change in body weight was calculated. 
2. Measurement of food intake 
Weighed quantity of food was kept each day .Initial and final weight of food was observed 
for 24 hrs to calculate the food intake values are expressed in grams /24hrs or grams per day 
3. Measurement of water intake 
         Initial and final amount of water observed for 24hrs to calculate the water intake values 
are expressed in grams/24hrs or grams / day 
4. Collection and analysis of urine 
        All animals are kept in individual metabolic cages and urine samples of 24hrs were 
collected on 28
th
day . Animals had free access to drinking water during the urine collection 
period. A drop of concentrated HCL was added to the urine befor being stored at 4
0
 C. The 
following urine contents were analysed.  
7.2.IN VITRO STUDIES ON ANTINEPHRO-LITHIATIC EFFECT OF ETHANOLIC 
EXTRACT OF Apium Graveolens (EEAG) 
To estimate the efficacy of the EEAG in preventing the various stages involved in 
urolithiasis, the aggregation and nucleation assay were performed with EEAG and compared 
with the negative control. 
Nucleation Assay 
Solutions of calcium chloride and sodium oxalate were prepared at a final concentration of 3 
mmol/l and 0.5mmol/l respectively, in a buffer containing tris 0.05 mol/l and NaCl 0.15 mol/l 
at pH 6.5. 950µl of calcium chloride solution was mixed with 100µl of herb extract at 
different concentrations. Crystallisation was started by adding 950µl of sodium oxalate 
solution. The final solution was magnetically stirred at 800 rpm. The temperature was 
maintained at 37
o
c. the OD of the solution was monitored at 620 n. The rate of nucleation 
was estimated by comparing the induction time in the presence of extract with that of the 
control. 
% 𝑰𝒏𝒉𝒊𝒃𝒊𝒕𝒊𝒐𝒏 =
𝑶𝑫 𝒐𝒇 𝑺𝒂𝒎𝒑𝒍𝒆
𝑶𝑫 𝒐𝒇 𝒄𝒐𝒏𝒕𝒓𝒐𝒍
× 𝟏𝟎𝟎 
 Aggregation Assay 
Calcium oxalate crystals (COM) were prepared by mixing calcium chloride and sodium 
oxalate at 50 mmol/l. Both solutions were equilibrated to 60
o
c in a water bath for 1 hr and 
then cooled to 37
o
c overnight. The crystals were harvested by centrifugation and then 
evaporated at 37
o
c. COM crystals were used at a final concentration of 0.8mg/l, buffered with 
Tris 0.05 mol/l and NaCl 0.15 mol/l at pH 6.5. Experiments were conducted at 37
o
c in the 
absence and presence of the plant extract. The rate of aggregation was estimated using the 
formula given below 
% 𝑰𝒏𝒉𝒊𝒃𝒊𝒕𝒊𝒐𝒏 = 𝟏 −
𝑻𝒖𝒓𝒃𝒊𝒅𝒊𝒕𝒚 𝒐𝒇 𝒔𝒂𝒎𝒑𝒍𝒆
𝑻𝒖𝒓𝒃𝒊𝒅𝒊𝒕𝒚 𝒐𝒇 𝑪𝒐𝒏𝒕𝒓𝒐𝒍
× 𝟏𝟎𝟎 
 
7.3.BIO-CHEMICAL ANALYSIS 
 
At the end of the study on 29
th
day , the animals were sacrificed under light ether anaesthesia. 
The rats were sacrificed by decapitation and blood was collected by bleeding of cardiac 
puncture  using centrifuge tubes from all the groups of overnight fasted rats and serum was 
separated to study the bio-chemical parameters. 
Serum analysis 
Blood was collected from the rats in each group after sacrificing the animals, and serum was 
separated by centrifugation at 6000 rpm for 15 min and analyzed for SGOT, SGPT,
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 Serum 
urea, Uric acid and Creatinine. 
Estimation of Urea: 
       Ammonia and Carbon dioxide (CO2) are produced when urea is hydrolyzed in presence 
of Urease. The Ammonia produced in the reaction combines with 2- Oxoglutarate and NADH 
in the presence of Glutamate dehydrogenase (GLDH) to yield glutamate and NAD+ . The 
NADH/NAD+ reaction produces a unique change in absorbance at 340 nm, which correlates 
with the concentration of urea nitrogen in the sample. 
 
Estimation of Uric acid: 
       Uric acid is oxidized to peroxide in presence of an enzyme uricase. The peroxide reacts 
with ADPS and aminoantipyrine in the presence of an enzyme peroxidase to form a Blue 
purple quinoneimine dye. The intensity of the Blue purple colour is proportional to the uric 
acid concentration and is determined photometrically 
Estimation of SGPT: 
It is an enzymatic method, which measure gultamic pyruvate transaminase  in serum 
according to Reitman and Frankel (1957), and Schmidt and Schmidt, (1963). 
Principle: 
Alanine amino transfers is measured by monitoring the concentration of pyruive hydrazone 
formed with 2-4 dinitrophenylhydrazine . 
Reaction: 
α - oxoglutarate + L-alanine ALT L-glutrate + pyruivate 
The absorbance of samples was read against the reagent blank after 5min at 
wavelength 546 nm in spectrophotometer. 
Estimation of SGOT : 
It is an enzymatic method that measure gultamic oxaloacetic transaminase in serum according 
to Reitman and Frankel (1957), and Schmidt and Schmidt,(1963). 
 
Principle: 
Aspartate amino transferase is measured by monitoring the concentration of oxaloacetate 
hydrozone formed with 2-4 dintrophenyl hydrazine. 
Reaction: 
α- oxoglutarate +L-aspartate AST L-glutarate + oxaloacetate 
The absorbance of samples was read against the reagent blank after 5min at wavelength 546 
nm in spectrophotometer and cuvette of 1cm light path. 
Haematological studies: 
Haemoglobin concentration (Hb), packed cell volume (PCV), red blood cells 
count (RBC), mean corpuscular volume (MCV), and mean corpuscular 
hemoglobin concentration (MCHC), were measured. 
Blood samples were collected into dry clean bottles; the anticoagulant was 
ethylene diamine tetra acetic acid (EDTA). 
Estimation of Creatinine:  
Serum creatinine was estimated using Alkaline picrate method. 
Reagents : 
Picric acid-0.04N 
Sodium hydroxide-0.75N 
Stock Creatinine (100mg/100ml 0f 0.1N Hcl was made up to 100 ml with distilled water) 
Procedure : 
0.1ml of the sample was made up to 2ml with water. To this 1ml of picrate and 1ml of 
sodium hydroxide was added and mixed well and allowed to stand for 15 min at room 
temperature. 
Standard was treated in same manner. After the incubation period the optical density was 
measured at 560nm against the blank. Creatinine values were expressed in mg/dl. 
 
7.3.Urine Analysis 
 
       24 hrs urine sample was collected and calcium, magnesium, urea, uric acid and creatinine 
were estimated by using standard procedure as follows
82
. 
Estimation of Urinary Calcium and Magnesium level 
1. To a 15ml conical centrifuge tube add 10 ml of well shaken urine , 2 drops of methyl 
orange , concentrated HCL dropwise , to a red colour and 1ml of 5% ammonium 
phosphate slowly with shaking. 
2. Add 2ml of ammonium hydroxide (28%), mix and let stand for at least 1 hour. 
3. Centrifuge , decant and wash the precipitate 3 times with 5 ml of alcohol wash. 
4. Dissolve the precipitate with 0.5ml of HCL and wash quantitatively in to a 10ml 
volumetric flask, bring to volume with distilled water and mix.  
5. 5ml of the aliquot from item (4) are taken and 1ml of 2.5% oxalic acid  is added, as 
well as a drop of methyl orange . Sodium acetate solution is then added slowly until 
the Ph is approximately 4. The mixture is then allowed to stand for 4hrs or more for 
the complete precipitation of the calcium oxalate . 
6. The precipitate of calcium oxalate is then centrifuged and washed twice with 3 ml of 
2% ammonium hydroxide . The supernatant and the washings are saved for the 
magnesium determination 
7. The calcium oxalate precipitate is dissolved in 0.5ml of 1:4 Hcl and 5ml of water, 
0.5ml of 5% ammonium phosphate and 2ml of ammonium hydroxide are added and 
mixed to re-precipitate the calcium as the phosphate . After allowing this to stand for 
1 hr or more . It is centrifuged and the precipitate washed twice with the alcohol wash. 
The precipitate may be used for the phosphorus determination ,depending upon the 
amount of calcium present. 
8. To the supernatanat and the washing from the above 0.5ml of ammonium phosphate 
solution and 2ml of strong ammonia are added and allowed to stand for 1 hr or longer. 
The precipitate is centrifuged and washed twice with 5 ml of alcohol wash and then 
redissolved in Hcl. Phosphate analysis is then performed step(5), (3) the magnesium 
ammonium phosphate from step (9). 
9. Spectral range 500-570 nm83. 
Estimation of Urinary Phosphate 
A simple qualitative method to determine the presence of phosphate ions in a sample 
is as follows. A small amount of the sample is acidified with concentrated nitric 
acid to which a little ammonium molybdate is added.  
The presence of phosphate ions is indicated by the formation of a bright yellow precipitate 
layer of ammonium phosphomolybdate.
105 
Reagents : 
 
a) 10% TCA 
b) Ammonium molybdate -2.5% in 5N HCL 
c) ANSA -0.5gm of ANSA was dissolved in 5ml of 20% sodium sulphate and then 195 
ml of 15% Sodium meta bisulphite was added. Stirred well, filtered and stored in 
brown bottle. 
d) Standard concentration of 8µg/ml was prepared from the stock Potassium dihydrogen 
phosphate(35.1 mg/100ml) 
 
Procedure : 
 
0.1ml of sample , 4.4 ml of distilled water, 0.5ml of ammonium molybdate, 0.2ml of ANSA 
was added and mixed well . The readings were taken after 20mins at 650nm. 
 
Phosphorus values were expressed in mg/dl 
7.4.Kidney histopathology 
The isolated right kidney was preserved in 10% formalin solution. Sections were cut with 5 
µm thickness and using 4 Leica RM-2126 microtome, they were mounted on slides after 
staining with hematoxylin and eosin. The slides were observed under light microscope to 
study the kidney architecture and CaOx deposits. 
7.5.Statistical Analysis 
Results were expressed in terms of mean ± standard error mean. Differences among data were 
determined using one-way ANOVA test followed by Dunnett's multiple comparison test 
(GraphPad Software, Inc., version 5, CA, USA.) and P < 0.05 was considered statistically 
significant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.RESULTS 
 
In this present investigation, an attempt has been made to find out the possible in vivo 
antiurolithiatic activity of ethanolic extract of Apium graveolens. 
  
8.1.Preparation of Extraction 
Extraction was done by solvent evaporation method with Soxhlet apparatus. The yield of 
extraction was found to be 12% w/w. 
 
8.2.PRELIMINARY PHYTO CHEMICAL ANALYSIS OF ETHANOLIC 
EXTRACT OF APIUM GRAVEOLENS 
The result of preliminary phytochemical  analysis  of  Ethanolic extract of Apium graveolens 
was shown in the Table no.3. 
The ethanolic extract of Apium graveolens (EEAG) showed presence of various 
phytochemical constituents such as Alkaloids,  Flavanoids, Glycoside,  tannins, Phenols and 
steroids. 
 
 
 
Tableno : 3 Phytochemical screening of Apium Graveoelens 
 
 Phytochemical studies 
   
TESTS  OBSERVATION 
Alkaloids   
1.Drogendroff’s test  + 
2. Wagner’s test  + 
3.mayer’s test  + 
Flavanoids  + 
Saponins  Traces 
Carbohydrates  
1. Fehlings test + 
2. Benedicts test + 
3. Mollischs test + 
Phenols   
1. Ferric chloride test + 
2. Lead acetate test + 
3. Liebermanns test + 
Steroid   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
8.3. IN VITRO RESULTS 
Effect of EEAG on Nucleation Assay 
Table No : 4 – Invitro nucleation assay results 
Concentration 
(mg) 
Absorbance 
(nm) 
Control 0.176 
0.5 0.127 
1.0 0.108 
 
Effect of EEAG on Aggregation Assay 
Table No:5 – Invitro aggregation assay results 
 
Concentration 
(mg) 
% Inhibition of aggregation 
At 90 min interval At 180 min interval 
Control 0 0 
0.5 1.25 45.11 
1.0 5.11 17.75 
 
 
 
 
 
 
 
 
 
1. Libermanns-Burchards test + 
2. Salkowsi reaction + 
Glycosides + 
Tannins   
1. Ferric chloride test + 
2. Lead acetate test + 
Terpenoids - 
Sterols Traces 
 (+)……….. Positive (-)........... Negative 
 8.4.ANIMAL STUDIES 
Results of Acute oral toxicity Study: 
The Acute Oral Toxicity study was done according to the OECD Guidelines 423 { Acute 
toxic class method }. A single dose of 2000 mg/kg b.w / p.o EEAG was administered to three 
rats and observed for 3 days. There was no considerable change in body weight before and 
after treatment and no sign of toxicity was observed. No change was observed from first set 
of experiment. Results are showed in Table  
Acute Oral Toxicity studies of EEAG (OECD 423 Guidelines) 
Table No :6 – Acute oral toxicity Effect on Ethanolic extraction of Apium 
graveolens seeds 
S.no 
Treatme
nt group 
Dose 
Weight of the 
animal in grams Signs 
of 
toxicity 
Onset 
of 
toxicity 
Reversible 
or 
Irreversible 
Duration 
Before 
test 
After 
test 
1 EEAG 2g/kg 210 220 
No signs 
of 
toxicity 
Nil Nil 14 Days 
2 EEAG 2g/kg 210 230 
No signs 
of 
toxicity 
Nil Nil 14 Days 
3 EEAG 2g/kg 250 260 
No signs 
of 
toxicity 
Nil Nil 14 Days 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.5.Antinephrolithiatic activity of EEAG 
 
GENERAL PARAMETERS : 
EFFECT OF EEAG ON BODY WEIGHT 
A Significant decrease in body weight (p<0.05) was observed in negative control when compared to 
the control group. The group (3,4,5) treated with EEAG showed significant (**p<0.01).(*p<0.05) 
shows increase in body weight when compare to negative control. 
The results were shown in the Table no.7 and Figure no.9.  
EFFECT OF EEAG ON FOOD INTAKE 
 A Significant (**p<0.01,***p<0.001) decrease in food intake was seen at negative control than the 
control group. The group (3,4,5) treated with EEAG shows significant (**p<0.01)(***p<0.001) there 
is the increase in food intake when compared to the negative control. 
The results were shown in the Table no.8 and Figure no.10.  
EFFECT OF EEAG ON WATER INTAKE 
A Significant (*p<0.01,**p<0.001) decrease in water intake was seen at negative control than the 
control group. The group (3,4,5) treated with EEAG shows significance (*P<0.05,**P<0.01) increase 
in intake of food when compared to the negative control. 
The results were shown in the Table no.9 and Figure no.11.  
EFFECT OF EEAG ON URINE VOLUME 
A Significant (*p<0.05,**P<0.01) decrease in urine volume is observed in negative control when 
compared to the control. The group treated with the EEAG shows significance (*p<0.01) increase in 
the urine volume when compared to the negative control. 
The results were shown in the Table no.10 and Figure no.12.  
 
 
Effect of EEAG on Body weight in grams: 
TABLE: 7-Effect of EEAG on Body weight in grams 
GROUP 
BODY WEIGHT 
14th day 28th day 
Control 192.000 ±4.063 208.555 ±3.333 
Negative Control 175.663  ±6.666*a 182.666 ± 6.009*a 
Standard 205.555 ±7.719*b 226.333± 8.279*b 
EEAG 200mg/kg 195.555 ±18.559**b 200.666± 4.409**b 
EEAG 400mg/kg 185.000 ±4.582*b 216.333± 2.279*b 
Values are expressed as Mean ±  SEM, n=6 
Comparison : a -Group I vs Group II  
                       b- Group II vs Group III,  IV& V;NS  Non significant; 
*P<0.05, **P<0.01;***P<0.001 
One way ANOVA followed by Dunnet’s ―t‖ Test 
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Figure No: 9 :Effect of EEAG on Body weight in grams 
Effect of EEAG on Food Intake in grams: 
TABLE :8 Effect of EEAG on Food intake gm/ 24 hr 
GROUP 
FOOD INTAKE 
14th day 28th day 
Control 67.500± 0.907 75.166± 0.333 
Negative Control 48.900± 3.450**a 42.300 ± 3.963***a 
Standard 61.696± 3.758*b 74.633± 3.35*b 
EEAG 200mg/kg 52.677± 2.628**b 68.100± 2.79**b 
EEAG 400mg/kg 
54.309± 3.081**b 74.300 ± 2.63*b 
Values are expressed as Mean ±  SEM, n=6 
Comparison : a -Group I vs Group II  
                       b- Group II vs Group III,  IV& V;NS  Non significant; 
*P<0.05, **P<0.01;***P<0.001 
One way ANOVA followed by Dunnet’s ―t‖ Test 
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Figure No : 10Effect of EEAG on Food intake gm/ 24 hr 
Effect of EEAG on Water intake in ml/24hr: 
Table : 9 Effect of EEAG on Water intake in ml/24hr 
GROUP 
WATER INTAKE 
14th day 28th day 
Control 
35.600±1.233 36.377±1.005 
Negative Control 
24.533± 1.426**a 13.433± 0.520***a 
Standard 
32.100± 0.702*b 33.333± 0.440**b 
EEAG 200mg/kg 
30.733± 0.959**b 32.533± 0.688*b 
EEAG 400mg/kg 
26.655± 0.866*b 31.766± 0.176*b 
Values are expressed as Mean ±  SEM, n=6 
Comparison : a -Group I vs Group II  
                       b- Group II vs Group III,  IV& V;NS  Non significant; 
*P<0.05, **P<0.01;***P<0.001 
One way ANOVA followed by Dunnet’s ―t‖ Test 
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Figure No : 11 Effect of EEAG on Water intake in ml/24hr 
Effect of EEAG on Urine output in ml/24hr 
Table :10  Effect of EEAG on Urine output in ml/24hr 
GROUP 
URINE OUTPUT 
14th day 28th day 
Control 10.55± 0.72 9.67± 0.56 
Negative Control 7.55± 0.23**a 5.25± 0.35**a 
Standard 10.88± 0.5***b 9.12± 0.62***b 
EEAG 200mg/kg 8.44± 0.2*b 6.25± 0.4*b 
EEAG 400mg/kg 9.22± 0.41**b 7.95± 0.8**b 
Values are expressed as Mean ±  SEM, n=6 
Comparison : a -Group I vs Group II  
                       b- Group II vs Group III,  IV& V;NS  Non significant; 
*P<0.05, **P<0.01;***P<0.001 
One way ANOVA followed by Dunnet’s ―t‖ Test 
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Figure No : 12  Effect of EEAG on Urine output in ml/24hr 
BIO-CHEMICAL PARAMETERS 
EFFECT OF EEAG ON CREATININE 
There was significant (p<0.01) increase in serum creatinine in ethylene glycol induced group 
when compared to control group. There was significant (p<0.01) decrease in creatinine in 
thiazide treated group when compared to control group. There was significant (p<0.05) 
decrease in serum creatinine in EERI treated group at a dose of 200mg/kg/po when compared 
to control group. There was significant (p<0.001) decrease in creatinine in EERI treated 
group at a dose of 400mg/kg/p.o when compared to control group. 
    There was a significant (p<0.01) decrease in serum creatinine in thiazide treated rats when 
compared ethylene glycol induced pump. The EERI at a dose of 200mg/kg/p.o showed a 
significant (p<0.01) decrease in serum creatinine when compared to ethylene glycol induced 
group. The EEAG at a dose of 400 mg/kg/p.o showed a significant (p<0.001) decrease in 
creatinine when compared to ethylene glycol induced group.  
The results were shown in the Table no11.and Figure no.13.  
EFFECT OF EEAG ON URIC ACID 
There was significant (p<0.01) increase in uric acid in ethylene glycol induced group when 
compared to control group. There was significant (p<0.05) decrease in uric acid in thiazide 
treated group when compared to control group. There was significant (p<0.01) decrease in 
thiazide in EEAG treated group at a dose of 200mg/kg/p.0 when compared to control group. 
There was significant (p<0.05) decrease in uric acid in EEAG treated group at a dose of 
400mg/kg/p.o when compared to control group. 
 There was a significant (p<0.01) decrease in Uric acid in thiazide treated rats when 
compared ethylene glycol induced pump. The EEAG at a dose of 200mg/kg/p.o showed a 
significant (p<0.01) decrease in serum creatinine when compared to ethylene glycol induced 
group. The EEAG at a dose of 400 mg/kg/p.o showed a significant (p<0.05) decrease in Uric 
acid when compared to ethylene glycol induced group.  
 
EFFECT OF EERI ON SGOT 
There was significant (p<0.01) increase in serum in ethylene glycol induced group when 
compared to control group. There was significant (p<0.05) decrease in serum SGOT in 
thiazide treated group when compared to control group. There was significant (p<0.01) 
decrease in serum SGOT in EEAG treated group at a dose of 200mg/kg/p.0 when compared 
to control group. There was significant (p<0.05) decrease in serum SGOT in EEAG treated 
group at a dose of 400mg/kg/p.o when compared to control group. 
 There was a significant (p<0.01) decrease in serum SGOT level in thiazide treated rats when 
compared ethylene glycol induced pump. The EEAG at a dose of 200mg/kg/p.o showed a 
significant (p<0.05) decrease in serum SGOT level when compared to ethylene glycol 
induced group. The EEAG at a dose of 400 mg/kg/p.o showed a significant (p<0.01) decrease 
in serum SGOT level when compared to ethylene glycol induced group. 
The results were shown in the Table no.11 and Figure no.14.  
 
EFFECT of EERI on SGPT 
 There was significant (p<0.001) increase in serum glutamic pyruvate transaminase level in 
ethylene glycol induced rats when compared to control group. There was significant (p<0.05) 
decrease in SGPT in thiazide treated group when compared to control group. 
There was significant (p<0.05) decrease in serum SGPT in EEAG treated group at a dose of 
200mg/kg/p.0 when compared to control group. There was significant (p<0.001) decrease in 
serum SGPT in EEAG treated group at a dose of 400mg/kg/p.o when compared to control 
group. 
    There was a significant (p<0.001) decrease in serum SGPT level in thiazide treated rats 
when compared ethylene glycol induced group. The EEAG at a dose of 200mg/kg/p.o 
showed a significant (p<0.05) decrease in serum SGOT level when compared to ethylene 
glycol induced group. The EEAG at a dose of 400 mg/kg/p.o showed a significant (p<0.001) 
decrease in serum SGOT level when compared to ethylene glycol induced group. 
The results were shown in the Table no 12.and Figure no.15.  
 
EFFECT of EERI on UREA 
 There was significant (p<0.001) increase in Urea level in ethylene glycol induced rats when 
compared to control group. There was significant (p<0.001) decrease in Urea in thiazide 
treated group when compared to control group. 
There was significant (p<0.05) decrease in serum Urea in EEAG treated group at a dose of 
200mg/kg/p.0 when compared to control group. There was significant (p<0.05) decrease in 
serum Urea  in EEAG treated group at a dose of 400mg/kg/p.o when compared to control 
group. 
    There was a significant (p<0.001) decrease in serum Urea level in thiazide treated rats 
when compared ethylene glycol induced group. The EEAG at a dose of 200mg/kg/p.o 
showed a significant (p<0.05) decrease in serum Urea level when compared to ethylene 
glycol induced group. The EEAG at a dose of 400 mg/kg/p.o showed a significant (p<0.05) 
decrease in serum Urea level when compared to ethylene glycol induced group 
The results were shown in the Table no 11.and Figure no.14. 
 
TABULAR COLUMN : 
Table :11  Effect of EEAG on Serum parameters – Creatinine, Urea, Uric 
acid 
GROUP 
SERUM PARAMETERS 
Creatinine Urea Uric acid 
Control 0.85± 0.115 18.22±0.51 0.83± 0.64 
Negative Control 1.000± 0.04**a 26.99±0.02***a 2.89± 0.63**a 
Standard 0.800± 0.005**b 20.26±0.16***b 1.17± 0.71*b 
EEAG 200mg/kg 0.910± 0.011*b 25.37± 0.18*b 1.10± 1.02**b 
EEAG 400mg/kg 0.752± 0.051***b 27.35± 0.22*b 1.76± 0.56*b 
 Values are expressed as Mean ±  SEM, n=6 
Comparison : a -Group I vs Group II  
                       b- Group II vs Group III,  IV& V;NS  Non significant; 
*P<0.05, **P<0.01;***P<0.001 
One way ANOVA followed by Dunnet’s ―t‖ Test 
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Figure No :13Effect of EEAG on Serum parameters – Creatinine 
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Figure No.14 Effect of EEAG on Serum parameters – Creatinine, Urea, Uric 
acid 
 
 
 
 
 
 
 
Table :12  Effect of EEAG on Serum parameters – SGOT & SGPT 
GROUP 
SERUM PARAMETERS 
SGPT SGOT 
Control 
35.06± 0.12 72.47± 0.17 
Negative Control 
53.47± 0.01**a 90.99± 0.01***a 
Standard 
 
37.80± 0.03*b 74.77± 0.19*b 
EEAG 200mg/kg 
 
35.56± 0.72**b 80.44± 0.22*b 
EEAG 400mg/kg 
40.98± 0.11*b 73.99± 0.01***b 
 
Values are expressed as Mean ±  SEM, n=6 
Comparison : a -Group I vs Group II  
                       b- Group II vs Group III,  IV& V;NS  Non significant; 
*P<0.05, **P<0.01;***P<0.001 
One way ANOVA followed by Dunnet’s ―t‖ Test 
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Figure No 15  Effect of EEAG on Serum parameters – SGOT & SGPT 
 
 
 
 
 
 
 
 
 
URINE PARAMETERS 
EFFECT OF EEAG ON URINARY CALCIUM 
There was significant (p<0.01) increase in urinary calcium level in ethylene glycol induced 
rats when compared to control rats. There was significant (p<0.05) decrease in urinary 
calcium in thiazide treated group when compared to control group. There was significant 
(p<0.01) decrease in urinary calcium in EERI treated group at a dose of 200mg/kg/p.0 when 
compared to control group. There was significant (p<0.05) decrease in urinary calcium in 
EERI treated group at a dose of 400mg/kg/p.o when compared to control group. 
 There was a significant (p<0.01) decrease in urinary calcium in thiazide treated group when 
compared ethylene glycol induced group. The EEAG at a dose of 200mg/kg/p.o showed a 
significant (p<0.01) decrease in urinary calcium when compared to ethylene glycol induced 
group. The EERI at a dose of 400 mg/kg/p.o showed a significant (p<0.05) decrease in 
urinary calcium when compared to ethylene glycol induced group. 
EFFECT OF EEAG ON URINARY MAGNESIUM 
There was significant (p<0.01) increase in urinary magnesium level in ethylene glycol 
induced rats when compared to control rats. There was significant (p<0.001) increase in 
magnesium in thiazide treated group when compared to control group. There was significant 
(p<0.05) increase in magnesium in EERI treated group at a dose of 200mg/kg/p.0 when 
compared to control group. There was significant (p<0.05) increase in magnesium in EERI 
treated group at a dose of 400mg/kg/p.o when compared to control group. 
    There was a significant (p<0.01) increase in urinary magnesium in thiazide treated group 
when compared ethylene glycol induced group. The EERI at a dose of 200mg/kg/p.o showed 
a significant (p<0.05) increase in urinary magnesium when compared to ethylene glycol 
induced group. The EERI at a dose of 400 mg/kg/p.o showed a significant (p<0.05) increase 
in urinary magnesium when compared to ethylene glycol induced group.  
The results were shown in the Table no.4 and Figure no.9.  
 
EFFECT OF EEAG ON URINARY PHOSPHATE  
A Significant (**p<0.01) increase in phosphate is observed at ethylene glycol induces rats 
when compared to the control group. There was significant (p<0.01) decrease in urinary 
phosphate in thiazide treated group when compared to control group. There was significant 
(p<0.01) decrease in urinary phosphate in EEAG treated group at a dose of 200mg/kg/p.0 
when compared to control group. There was significant (p<0.05) decrease in urinary 
phosphate in EEAG treated group at a dose of 400mg/kg/p.o when compared to control 
group. 
 There was a significant (p<0.01) decrease in urinary phosphate in treated group when 
compared ethylene glycol induced group. The EERI at a dose of 200mg/kg/p.o showed a 
significant (p<0.01) decrease in urinary phosphate when compared to ethylene glycol induced 
group. The EEAG at a dose of 400 mg/kg/p.o showed a significant (p<0.05) decrease in 
urinary phosphate when compared to ethylene glycol induced group. 
 
Table :13 Effect of EEAG on Urinary parameters -Calcium , Magnesium 
and Phosphate. 
GROUP URINE PARAMETERS 
Calcium Magnesium Phosphate 
Control 
2.733± 0.520 0.20± 0.13 4.807± 0.606 
Negative Control 
5.800± 0.603**a 0.36± 1.04**a 8.520± 0.952**a 
Standard 2.613± 0.58*b 
0.22± 0.69***b 4.607± 0.555**b 
EEAG 200mg/kg 2.544± 0.317**b 
0.27± 0.66*b 4.033± 0.543**b 
EEAG 400mg/kg 
2.722± 0.548*b 0.28± 0.78*b 5.001± 0.544*b 
 
 
Values are expressed as Mean ±  SEM, n=6 
Comparison : a -Group I vs Group II  
                       b- Group II vs Group III,  IV& V;NS  Non significant; 
*P<0.05, **P<0.01;***P<0.001 
One way ANOVA followed by Dunnet’s ―t‖ Test 
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Figure No : 16 Effect of EEAG on Urinary parameters -Calcium and 
Phosphate. 
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No.17  Effect of EEAG on Urinary parameters - Magnesium 
 
 
 
 
 
 
 
 
HISTOPATHOLOGY RESULTS 
Effect of EEAG on Renal stones 
a) GROUP-I  Control 
 
 
 
 
 
 
Effect of EEAG on Renal Stones 
b) GROUP-II  Negative Control 
 
 
 
 
 
 
 
 
Effect of EEAG on Renal Stones 
Figure 18 
Figure 19 
c) GROUP-III Standard 
 
 
 
 
 
 
a) GROUP-IV High dose    d)  GROUP-IV High dose 
 
 
 
 
 
 
 
9.DISCUSSION 
 Estimated life time risk of Urolithiasis in Asia 2%-5%, 8%-15% in Europe and 
America and around 20% in middle east. It is associated with a high risk of reoccurrence 
which is around 10%-23% per year 50% in 10 years and 75% in 20 years. 
 Stones may occur in any part of the urinary system like kidney, ureter, bladder, and 
one of the most painful diseases. Urinary lithiasis is due to imbalance between inhibitors and 
Figure 20 
Figure 21 Figure 22 
promoters in the kidneys. Urinary super saturation is the driving force behind crystal 
formation in the kidneys. Since formation of crystalline particles must obviously start from 
super saturation. Super saturation is undoubtedly essential for stone formation. The initial 
step in the transformation from a liquid to a solid phase in a supersaturated solution is called 
nucleation. This process begins with the coalescence of stone salts in solution into loose 
clusters that may increase in size by addition of new components or clusters. Once a crystal 
nucleus has achieved a critical size and relative supersaturation remains above 1, overall free 
energy is decreased by adding new crystal components to the nucleus. This process is called 
crystal growth. Aggregation is a process in which the salts in the solution stick together to 
form larger particles. Some researchers have Crystallization is caused by the condition of 
urinary supersaturation. Then, the crystals that have formed attach to renal tubular epithelial 
cells and are taken into them; crystal aggregation is the most important step in stone 
formation. 
 Apium graveolens seeds  are commonly usedin the nativesystem of medicine. Various 
parts of the plant like leaves and roots are medicinally important.  
In order to investigate the medicinal use of Apium graveolens in urolithiasis, we evaluated 
crude extract for its antiurolithic activity using different in vitro assays and in vivo rat model 
of urolithiasis. 
 Calcification is a multifactorial phenomenon
96
 developing as a result of a cascade of 
events initiated by supersaturation, including crystal nucleation, growth, aggregation and 
retention
97
 Crystal inhibitors thiazide like have been shown to decrease the saturation of 
CaOx and inhibit crystal nucleation, growth and aggregation, while reduced crystallization in 
urine of stone forming inn rats 
98
. Interference with crystal growth and aggregation therefore 
seems a possible therapeutic strategy for the prevention of recurrent stone disease. 
Preliminary Phytochemical analysis of ethanolic extract of Apium graveolens had  showed 
the presence of Phytoconstituents like alkaloids, flavonoids, tannins, saponins and Cardiac 
glycosides. Flavanoids and alkaloids are widely distributed in the plant which have the 
property to cure urolithiasis. Due to this reason the plant has chosen to this study.  This shows 
that the EEAG may contain substances that inhibit CaOx crystal aggregations and thus 
preventing a critical step in urinary stone formation, as larger particles are less likely to pass 
spontaneously in urinary tract. If the extract keeps CaOx particles dispersed in solution they 
can be easily eliminated 
99
. 
 Decrease in body weight in ethylene glycol and ammonium chloride treated group 
was observed. There is no change in body weight in Thiazide treated group and there was a 
significant Increase in body weight of EEAG  treated group given at both the doses of 200 
mg/kg and 400 mg/kg. 
 On examining the renal function tests of ethylene glycol and ammonium chloride 
induced animals, the excretion of uric acid, urea, creatinine and calcium has significantly 
increased and magnesium has significantly decreased with that of the control group. After 
treatment with the ethanolic extract of Apium graveolens (200 mg/kg and 400 mg/kg) the 
excretion of uric acid, urea, creatinine and calcium has significantly decreased and the 
excretion of magnesium has significantly increased. Although the low dose was more potent 
than the high dose when compared with thiazide treated group, which is a standard. 
 Ethanolic  extract of Apium graveolens has shown promising in vitro efficacy on 
urolithiasis, we have observed increase in the absorbance indicating the inhibition of 
Nucleation and Aggregation of calcium oxalate in in vitro studies. 
 For the in vivo antiurolithic effect of EEAG, 0.75% ethylene glycol (EG) and 1% 
ammonium chloride (AC)-induced hyperoxaluric rat model of urolithiasis was used. Since the 
stone inducing treatment, Ethylene glycol (EG), was given orally, therefore, the extract was 
given i.p. in order to prevent any potential interaction of EG with plant constituents inside 
gut, interfering with absorption of either of the two. Administration of EG and AC resulted in 
the increased CaOx crystalluria, with larger crystals due to hyperoxaluria, increase in water 
intake and urine output, which might be due to the renal impairment 
100 
as evident by 
increase in serum creatinine, blood urea  in lithiatic group as compared to normal
101,102 
 There was hypertrophy and extensive CaOx crystal deposition in kidneys of untreated 
rats. The renal tubules were markedly dilated, which might be due to the obstruction in distal 
renal tubular flow by large crystals 
100
Several in vivo and in vitro studies have demonstrated 
that hyperoxaluria, a major risk factor for calcium oxalate nephrolithiasis, results in greater 
production of superoxide and hydroxyl free radicals, leading to antioxidant imbalance, cell 
membrane rupture and cell death 
103
which leads to CaOx crystal adherence and retention in 
renal tubules 
104. 
Thus, it can be speculated that the inhibitory effect of the plant extract on 
CaOx crystal deposition in renal tubules is possibly caused by its antioxidant activity. The 
plant is considered relatively safer, as it has been used in different herbal preparations and 
supplements , is used in humans for ailment of diabetic and urinary disorders, which has also 
undergone clinical trials for several studies, with no reported side effect, for anti-
inflammatory and noci captive properties 
 Thus, these data suggest that the effect of EEAG in urolithiasis is mediated its effect 
through multiple pathways including inhibition of the CaOx crystal aggregation, which 
provide a step forward for designing further studies on EEAG to establish its safety and 
efficacy for clinical use. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10.SUMMARY AND CONCLUSION 
 Urolithiasis is one of the most painful urological disorder when compared to the other 
painful disorders. Kidney stone disease has afflicted human kind since antiquity and can 
persist, with serious medical consequences, throughout a patient’s life time. In addition, the 
incidence of kidney stones has been increased in most societies in the last five decades, 
especially in association with economic development. In spite of tremendous advances in the 
field of medicine, there is truly no satisfactory drug for the treatment of nephrolithiasis. 
 Recently, there is increasing evidence that many healthy natural food and medicinal 
herbal and supplements have the potential to become valuable complementary therapy in the 
treatment of various renal disorders and in the protection against nephrotoxicity. 
 The plant Apium graveolens is traditionally used for in different disorders such as 
anti-inflammatory activity, anticancer, antidiabetic, , hepatoprotective activity, etc.. An 
attempt was made to study urolithiatic activity in ethylene glycol and ammonium chloride 
induced method. 
 The preliminary phytochemical analysis of EEAG showed the presence of alkaloids, 
carbohydrates, cardiac glycoside, sterols & saponins, tannins, flavonoids are used against 
urolithiasis. 
 The anti-urolithiasis activity of Apium graveolens seeds is may be due to the presence 
of flavonoids and tanins. 
 Animals were divided in to 5 groups . Group I-Control, Group II-Negative control, 
Group III-Treated with standard drug, Group IV-Treated with Lower dose , Group-IV- 
Treated with higher dose. Data comparison was made between Group I – Group V 
.Urolithiasis was induced by feeding Ethylene glycol with ammonium chloride for 28 days. 
Statistical significance was done by ANOVA , followed by Dunnett’s multiple comparison 
test 
 
 CaOx and CaP deposition in the kidneys of EG and ammonium chloride fed animals . 
Treatment with EEAG (200/400 mg/kg) for 14 days successfully prevented the 
elevation of deposition of CaOx , phosphate in kidney when compared to the standard 
drug. 
 Significant decrease in Body weight, Feed intake, water intake observed in EG fed 
animals . Treatment with EEAG (200/400 mg/kg) for 14 days successfully increases 
the Body weight, water intake and food intake , when compared to the standard drug.  
 Increased urinary excretion of urinary calcium , oxalate, and phosphate are observed 
in EG and ammonium chloride fed animals . Treatment with EEAG (200/400 mg/kg) 
for 14 days successfully decreased the excretion of oxalate, calcium, phosphate when 
compared to the standard drug. 
 Serum creatinine , uric acid, Urea increased in EG and ammonium chloride fed 
animals due to decreased GFR. Treatment with EEAG (200/400 mg/kg) for 14 days 
successfully decreases the serum creatinine, uric acid, Urea when compared to 
standard drug. 
 Histo pathological findings of the EG fed animals are distended tubules, dilation and 
deposition of crystals. The histopathology of kidney was brought to normal in EEAG 
treated animals when compared to the standard drug. 
 
 The present study indicates that the administration of EEAG to rats in ethylene glycol 
and ammonium chloride induced urolithiasis reduces the growth and development of kidney 
stones by reducing the stone forming constituents by increasing the GFR . Accordingly, it can 
be concluded that the supplementation of Apium graveoelns has a beneficial effect on 
urolithiasis . 
 
 Further studies are needed to identify the molecular mechanism of Apium graveoelns  
and the structural elucidation of phytoconstituents responsible for antiurolithiasis 
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